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ABSTRACT
The effects of oestrogen on renal and systemic haemodynamics, 
intrarenal vasoactive substances and plasma volume status have been 
studied in adult female normotensive and spontaneously hypertensive
rets.
Administration of oestrogen to both strains of rat resulted in 
a reduction in renal blood flow, due to an increased renal vascular 
resistance in the presence of an increase in both plasma renin 
substrate concentration and activity.
In the normotenaive rat, oestrogen affected a rise in arterial 
pressure, accompanied by an expanded plasma volume, and either an 
unchanged or increased plasma renin activity. Whilst changes in 
arterial pressure were reciprocally related to changes in plasma 
volume, no relationship was noted between arterial pressure and 
plasma renin activity. In the spontaneously hypertensive rat, 
oestrogen caused a fall in arterial pressure, due to a reduced 
peripheral vascular resistance.
The oestrogen-induced reduction in renal perfusion was due to 
enhanced local, intrarenal generation of angiotensin II - as 
evidenced by an increase in renal perfusion in both strains of 
oestrogen treated rat after angiotensin converting enzyme inhibition 
(captopril). Evidence from studies involving prostaglandin synthesis 
inhibition (indomethacin), plasma prorenin activation (trypsin) and 
saralasin treatment (angiotensin II blockade)indicate that a 
proportion of this angiotensin II-mediated intrarenal vasoconstriction 
involved at least a prostaglandin-dependant pathway, in addition to 
an alteration in intrarenal vascular angiotensin II receptor density.
XI
The oestrogen-induced rise in arterial pressure was 
determined principally by plasma volume expansion, although 
angiotensin II also contributed to this rise - as demonstrated 
by a lessening of oestrogen-induced hypertension by captopril. 
The oestrogen-induced fall in arterial pressure appeared to be 
prostaglandin-dependant, although indomethacin failed to 
influence arterial pressure in oestrogen treated epcntaneously 
hypertensive rats.
This investigation demonstrates that an alteration in 
the normal equilibrium between intrarenal vasoactive 
substances can, in conjunction with a change in plasma volume 
status, lead to disturbances in both renal and systemic 
haemodynamics during oestrogen treatment.
XII
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1.1 TH* P M o l O U JQ IC A L  A u U i uf ThS îüLjiK L wi-iÇU^TION
In the kidney* as In the lung* only a relatively 
email proportion of the large fraction of cardiac output 
flowing through the organ (approximately 2 0 % ) la concerned 
with the nutrition of the tlasuea themaelvea. The greater 
part of this blood has to pass through a comollcated 
intrarenal pathway so that Its pH* osmolality and 
composition may be regulated. The anatomy and ohyslology 
of the renal circulation are thus of the greatest 
Importance not only to renal function Itself* but also to 
extrarenal processes, principally the maintenance of 
overall cardiovascular homeostasis. Thus, a low medullary 
perfusion rate, eeoecially in the oaollla, is critical 
for the efficient function of the countercurrent system, 
as this prevents the continuous washout of the osmolal 
gradient created by tubular function - thereby permitting 
the production of a hypertonic urine. Likewise, trans­
plantation of a healthy kidney often normalises blood 
pressure In patients with severe renal disease and 
accompanying hypertension.
Prom the above it is clear that precise control of 
the renal circulation Is central to normal renal 
physiology, and that the factors which both mediate and 
Influence this control have the potential to affect the 
regulation of both renal and systemic haemodynamics. A 
detailed description of the renal circulation may be 
found in Pourman and Moffat (1). The organisation of 
the principal renal blood vessels, and their juxtaposition 
to the functional unit of the kidney, the neohron, Is 
Illustrated In Figures 1.1 - 1.3-
Renal cortex
Major calices
Renal medulla
Renal papilla
Renal sinus
F igu re  1.1 illustrates the s tru c tu ra l organisation 
of the mammalian k id n e y  b y  means of. 
a longitudinal section th ro u g h  a human 
kidn e y.
Figure 1.2 depicts the basic arrangement of the 
principal blood vessels in the mamma­
lian kidney.
Juxtaglomerular 
cells, site of 
renin secretion
Prostaglandin 
synthesis in 
arterial elements 
of the cortex
Kallikrein 
synthesised in 
the distal nephron
Angiotensinogen 
and kininogen 
from plasma
Angiotensin II 
and
Prostaglandins 
formed here
C O R TE X  
Angiotensin l l # kinins 
and prostaglandins 
interact to modulate 
cortical blood flow.
MEDULLA
Angiotensin II 
and prostaglandins 
interact to 
regulate medullary 
blood flow
Figure  1.3 Schematic representation denoting potential roles 
of the renin  -  angiotensin and kallikrein -  kinin 
systems and renal prostaglandins as complementary 
modulators of the renal circulation (refer to te x t). 
Diagram is an expanded portion of Figure 1.2.
i.2 or THK 2
Renal blood flow Is subject to a type of control 
which seess to be sore highly developed In the kidney 
than In other organs. As arterial pressure Increases 
above 90 mm Hg, renal blood flow does not follow this 
Increase In pressure* but stays alaost constant. This 
so-called autoregulatlon of renal blood flow occurs within 
seconds* and has been found In Innervated, denervated and 
Isolated kidneys* and during blockade of lntrarenal 
ganglia. The Increase In vascular resistance which 
accompanies an Increase In perfusion oressure apnears to 
be a consenuence of wholly lntrarenal mechanisms.
It need be emphasised, that although renal perfusion 
is ordinarily little influenced by perfusion pressure, 
this does not aesn that Intrarenal perfusion Is not 
Influenced by a number of local factors (described below). 
It Is Indeed so Influenced under a variety of circumstances 
that the renal vascular response probably plays a pivotal 
role as a determinant of renal function.
Many hypotheses have been elaborated in an attempt 
to account for autoregulatlon. These hypotheses Include 
consideration of the effects of perfusion oressure and a 
number of endogenous vasoactive factors, including the 
renin-angiotensin and kallikrein-kinln systems, prosta­
glandins, noradrenaline and the sympathetic nervous 
system. No one mechanism has been shown to fully account 
for autoregulation, which Is undoubtedly under multi- 
factorial control. However, two main theories, the 
■yogenic and vasoactive theories, have gained widespread 
acceptance. According to the myogenic hypothesis the 
stimulus for the vascular smooth muscle contraction in
3
response to Increasing lntrslualnsl pressure is either 
the transmural pressure Itself» or the Increase In 
tangential tension of the vasculnr wall (2,3). According 
to this hypothesis the vascular snoot.n nuscle Is oressure 
or tension sensitive. The vasoactive hypothesis states 
that local vasoactive substances such as angiotensin II, 
prostaglandins or klnlns are released In response to 
changes In perfualon oressure, aporoprlately changing 
local vascular resistance (U,5). Whereas the weight of 
evidence available to date Is consistent with the nyogenlc 
hypothesis, the Involvement of local lntrarenal vasoactive 
substances in the control of renal blood flow Is less 
clearly defined.
Renin, a proteolytic enzyme, Is oroduced primarily 
In the renal cortex, with much smaller amounts being 
found In the uterus, placenta, salivary glands, brain and 
some blood vessels. In the kidney renin is synthesised 
In specialised cells, Juxtaglomerular cells, of the renal 
afferent arteriole. In Intimate contact with the distal 
tubule (13U,203,20U). The Juxtaglomerular cells are 
thought to be modified smooth muscle cells (205). The 
macula densa. Intimately associated with the Juxtaglonerula 
cells, consists of an elongated group of collumnar 
eoithellal cells situated in the distal convoluted tubule 
as It passes the glomerulus after it ascends from the 
medulla (205). Collectively, the Juxtaglomerular cells, 
macula uenaa and afferent glomerular arteriole are termed 
the Juxtaglomerular apparatus.
Due to Its unique structure and location (adjacent to 
the vascular oole of the glomerulus), early investigators 
postulated a role for the Juxtaglomerular apoaratus in the 
modulation of renal function. It was proposed that the
4
structure released nn »Kent that could fore or Activate 
a vasoactive substance which» In turn* Influenced local 
vascular tone 1200). The major area of Interest In this 
field was, however» oriented toward non-rensl functions 
such as In the control of aldosterone release» the regu­
lation of systemic cardiovascular function and the 
pathophysiology of hypertension (207). More recent 
Investigations have» nevertheless» provided Important 
evidence to auDport the contention of a physiological 
Involvement of a locally generated pressor substance» 
angiotensin II* In the regulation of renal vascular resistance
Renin secreted from the juxtaglomerular apparatus 
Into the renal vascular segment acta on a olasma oC-globulin. 
This anglotenslnogen« synthesised by the liver» serves as 
a substrate to split off a precursor decapeptlde, 
angiotensin I. Within the kidney angiotensin I does not 
exhibit any significant nresaor activity, and a specific 
converting enzyme, oroduced orlmarlly by the lung, solits 
two amino acids off the decaoeptlde to for* the active 
■olety, angiotensin II. The majority of angiotensin II 
Is thus generated In the DUlmonary circulation, and may be 
found distributed throughout the systemic circulation.
Angiotensin II is the most active endogenous 
vasoconstrictor substance identified to date, with an 
especially marked influence on the renal vasculature (6). 
.furaerous studies have Identified the vascular target site 
for angiotensin II. The presence of these receptors has 
been demonstrated in vascular smooth muscle from several 
tissues (208-210), and It la generally accented that smooth 
muscle cells of the renal vasculature possess similar 
receptors. In this context, recent studies have demon­
strated the presence of angiotensin receptors on intra- 
glomerular structure (211). Thus, cultured cells (of
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mesangial origin) from human glomeruli hare been shown 
to exhibit contractile activity (21?), an effect which 
may be mediated by angiotensin II (213).
The findings from studies which have utilised intra­
arterial Infusions of angiotensin II are orten cited as 
evidence supoortlng an Involvement of the hormone In the 
regulation of renal vascular resistance. These studies 
have shown that lntrarenal infusion* of low, subpressor 
doses of angiotensin II, which do not alter peripheral 
circulating angiotensin II levels (21U), consistently 
result in dose-dependant reductions In renal blood flow 
(213). This Information suggests that the Dressor erfect 
of angiotensin II on the renal vasculature could be mediated 
by preformed angiotensin II, delivered to the kidney In 
arterial blood.
The role of the renln-anglotensln system has also been 
investigated by inhibition of the formation of angiotensin II, 
with either a converting enzyme Inhibitor, or a oeptide 
antagonist that inhibits the interaction of angiotensin II 
with its tissue receotors. Early studies used animals In 
which prior activation of the renin-angiotensin system had 
been achieved, by manoeuvres such as sodium denletion, renal 
artery occlusion, vena cava constriction or high output 
heart failure. Here, pharmacological interruption of the 
renin-angiotensin system resulted in a reduction in renal 
vascular resistance, with consequent largo increases in 
renal blood flow (1^8,216,217). In most of these studies 
however, the changes noted in renal haemodynamics were 
associated with a reduction in mean arterial pressure.
More recently the infusion of angiotensin receotor 
antagonists intrarenally, at doses which only minimally 
affect blood pressure, has been achieved. As is the 
earlier studies this infusion also resulted in an increase
6
in renal blood rlow in animals with s previously activated 
renin-angiotensin system (218,219). This observation 
suggests that aside from a systemic node of action for 
angiotensin II, there is also a critical lntrarenal focus 
for conversion of angiotensin I to angiotensin II.
Powerful support for this thesis may be derived from reoorts 
which have demonstrated the presence of significant 
nuantitles of converting enzyme In renal tissue (220-222). 
Thus angiotensin II, generated intrarenally, may act as a 
local renal vascular hornone, aporopriately modulating 
renal vascular tone (9-11).
(liven the probability that angiotensin II is generated 
within the kidney and the hypersensitivity of the renal 
vessels to this substance, angiotensin II la Ideally suited 
to tne role or a local, physiological modulator or renal 
haemodynamics. Indeed, it would apoear that renin release, 
with subsenuent generation of angiotensin II, is the major 
determinant of renal oerfusion Dressure in situations where 
renal blood flow is compromised by either local factors such 
as lesions of the renal artery (12), or systemic factors 
such as diminished extracellular fluid volume (13).
During sodium depletion for examole, elevated renin- 
angiotensin system activity is a reouisite for maintenance 
of systemic blood pressure and renal blood flow. Thus, 
whilst infusion of the angiotensin II blocking agent, 
l-sar-8-ala angiotensin II, decreased blood oressure and 
glomerular filtration rate and increased renal blood flow 
in sodlum-deplete dogs, it had no such effect in sodium- 
reolete snimals, in which the activity of the renin- 
angiotensin system is normal (13). Under conditions of 
high renin release by the kidney therefore, angiotensin II 
may act as a regulator of renal blood flow to maintain 
glomerular filtration rate (1U).
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The contribution of other intrarenal hormonal system« 
to the control of renal blood flow is poorly defined, an 
many components of these systems are not, as yet, adeouately 
characterised, and many current assays employed to measure 
the activity of the systems are of uncertain specificity. 
Further, there is much inter-species variability in response 
to these hormones. However, there lr. a growing body of 
evidence to indicate that both the kailikrein-kinin system 
and renal prostaglandins form part of an important intrarenal 
hormonal regulatory complex which Includes the renin- 
angiotensin system.
Prostaglandins are 20-carbon unsaturated carboxylic 
acids derived from essential fatty acids, such as 
arachidonlc acid. Synthesis begins with the release of 
arachilonic acid from tissue stores, chiefly phospholipids, 
which is then acted upon by tissue cyclo-oxygeneee to 
recruit the prostaglandin component in response to diverse 
stimuli. All renal arterial elements appear to be capable 
of prostaglandin synthesis, including the main renal artery 
and the lobar and interlobular arteries with attached 
afferent arterioles (a site favouring interactions with renin).
Early studies which demonstrated that prostaglandins 
could dilate many vascular beds, and in particular, the 
renal vascular bed, led to the idea that prostaglandins 
may be important modulators of renal blood flow (15).
Whilst sutseouent studies have shown that the intrarenal 
administration of either prostaglandins (16) or arachidonlc 
acid (17) into the renal artery may cause a significant 
Increase in renal blood flow, more physiological doses of 
prostaglandins appear to exert a much smaller effect on 
renal blood flow. However, good evidence supporting s role 
for renal prostaglandins as renal vasodilators under normal
conditions« cone fron studies in which nharm*cologicai 
Inhibitors of prostaglandin synthesis hare been used. A 
number of studies have been performed which hare shown that 
the administration of prostaglandin synthesis inhibitors, 
such as lndomethacin and meclofenamatet resulted in a 
decrease in renal blood flow and an lncreaae in renal 
rmscular resistance (18,19).
Within the kidney kalllkreln is predominantly located 
within the cortex» membrane bound in tubules and apoears In 
urine fractions which originate from the distal nephron.
The enzyme is probably synthesised In an inactive precursor 
form, which can be activated by tryosln and other enzymes. 
When released, renal kallikrein releases the decapeptlde 
lysyl-bradykinln from a plasma alpha-globulin, kininogen. 
Klnlna are amongst the most potent vasodilator agents known. 
Although it is clear that administration of klnlns can 
alter renal blood flow (20) and sodium and water excretion 
(21), the role of klnins as ohyslological regulators of 
renal haemodynamics is less certain.
As stated earlier, the renin-angiotensin system, the 
kallikrein-klnin system and renal prostaglandins form an 
lntrarenal hormonal regulatory complex which contributes 
to the regulation of the renal circulation. The enzymes 
renin and kallikrein are formed and stored intrarenally; 
when released they act on plasma globulins to liberate 
decapeptides, angiotensin I and lysyl-bradykinin 
respectively. A single enzyme acts on both decapeptides, 
converting angiotensin I to the active hormone angiotensin 
II, and degrading kinins. Blockade of this enzyme with an 
inhibitor will augment the activity of the kallikrein- 
kinin system (22) and depress that of the renin-angiotensin 
system (23). Although kinins and angiotensin II have
opposing effects on the rensl circulation# they share an 
Important oroperty, the ability to ©romote prostaglandin 
synthesis and to alter the metabolism of prostaglandins 
(2U). Further, release of renin and kalllkreln is oartlally 
controlled by a prostaglandin mechanlsm(25,26). Thus, 
interactions between the renin-angiotensin and kalllkreln- 
klnin systems and renal prostaglandins (Fig. l.U) hare the 
potential for major modifications of the effects of these 
hormonal systems on renal haemodynamics (Fig. 1.3). Por 
example, vasodilators may be evoked to antagonise the 
vasoconstrictor action of angiotensin II, under conditions 
of high renin secretion, such as volume-deoletion (27,28).
1.3 THJfc KIDNSY A-*D OVERALL CARDIOVASCULAR H0ME03TA3I3
The renal circulation is subject to strict, 'Wlti- 
factorlal control of renal origin, so as to maintain 
efficient renal function. A healthy renal circulation is 
also vital to extrarenal processes, namely cardiovascular 
homeostasis. This fact is confirmed by the central role 
the kidney olays in the regulation of blood pressure.
Modern ideas of the involvement of the kidney in blood 
pressure control have evolved from workers such as Ooldblatt, 
whose classic experiment of 1963 showed that renal ischaemia 
precipitated hypertension in dogs. More recently, the 
antihypertensive action of a normal kidney has been 
demonstrated by transolantation. For instance, there are 
two types of rat hypertension which show the same effect.
In Dahl rats, for example, one can transplant a kidney from 
the D3 strain (susceptible to hypertension) to a DR rat 
(resistant to hypertension) and the blood pressure of the 
DR rat will rise. One can also do the opposite, taking a 
kidney from a DR rat and transplanting it to a D3 rat, and 
the blood pressure of the D3 rat will drop. The same 
patterns of change have also been observed after trans­
plantation in the Milan strain of
F ig u re  1 .4 . In tera ction s b etw een the re n in -a n g io te n s in , k a ll ik r e in - 
k in in  and p ro s ta g la n d in  system s. Solid a rro w s  indicate 
a stim u la to ry  p a th w a y  and th e  c ro ss -h a tc h e d  a rro w  an 
in h ib ito ry  p a th w a y .
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hypertensive rets. Similarly, when a person with end stage renal 
disease and severe hypertension receives a good kidney through 
transplantation, the blood pressure often returns to normal. 
Muirhead, (29) has reported that the renomedullary interstitial 
cells are the site of the antihypertensive action of the normal 
kidney.
These transplantation studies appear to demonstrate that the 
kidney can somehow carry the message of blood pressure and that 
the kidney can somehow command the level of blood presasure 
within the body. How might the kidney be able to achieve thie?* 
The kidney is the source of a number of vasoactive compounds 
which are concerned with the control of renal blood flow. The 
fact that these compounds have also been strongly implemented in 
the regulation of blood pressure demonstrates the importance of 
the control of the renal circulation to blood pressure control, 
and vice versa. The systemic hormone angiotensin II, is one of 
the most potent pressor agents known. Angiotensin II acts to 
constrict arterioles directly, it causes the adrenergic nerves to 
secrete more noradrenaline, the adrenal medulla to secrete more 
adrenaline. It acts upon specific receptors within the brain to 
cause an increased sympathetic nerve outflow. It acts on the 
adrenal glomeruloza to cause more aldosterone action and it seem9 
to act on renal tubules directly to cause sodium retention.
The vasodilatory properties of kinins and prostaglandins 
have been mentioned in relation to the control of the renal 
circulation. They may contribute to blood pressure regulation by 
maintaining the renal circulation in the face of pressor stimuli, 
contributing to the control of extracellular fluid volume and 
modulating the response of vascular smooth muscle to
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pressor stimuli. The theory that these mechanisms operste in 
vivo is supported by studies which have shown firstly, low urinary 
kallikrein levels (an index of kallikrein secretion) in essential 
hypertensives (30), and secondly, that administration of 
prostaglandin synthesis inhibitors elevated blood pressure and 
systemic vascular resistance in normotensive individuals (31) and 
elevated blood pressure levels further in hypertensive humans 
(32).
In summary, the control of renal blood flow and blood 
pressure is mediated through a number of common intrarenal 
pathways involving vasoactive compounds. A disturbance in either 
of these variables may result in an adverse effect on the other 
variable, with untoward consequences for both normal renal 
function and overall cardiovascular homeostasis.
1.4 THE INFLUENCE OF OESTROGEN ON THE RENAL CIRCULATION
Oestrogen-containing compounds are widely accepted as a 
simple and effective form of oral contraception. There is 
however, an increasing awareness of their undesirable side 
effects, some of which may be serious, such as hypertension. In 
spite of these adverse effects few, if any, would advocate the 
abandonment of oral contraceptives. The advantages of family 
planning by this means, and the short term preferences of human 
nature are such that most women would probably accept an even 
greater risk to avoid an unwanted pregnancy, bearing in mind the 
risks of pregnancy itself, including hypertension and toxaemia. 
The fact is that oral contraceptives are probably here to stay. 
Although the relative risk in users is large, the absolute risk 
is small for women under the age of forty. Nevertheless, with an 
already substantial and still growing percentage of the female 
population taking oral contraceptives regularly (an
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estimated 60 million worldwide in 1978), and likely to continue 
doing so for the reat of their reproductive lives, 'small risks' 
assume added significance.
Observations from a broad spectrum of studies involving the 
use of oestrogens suggest that these steroids may well have the 
capacity to exert a powerful influence on the renal circulation.
The first line of evidence sterna from the effect of 
oestrogen on one of the major cardiovascular risk factors, blood 
pressure. There ia now an overwhelming weight of evidence 
associating the use of oestrogen-containing oral contraceptives 
with the development of hypertension in certain susceptible women 
(33, 34). Practically all women ingesting oestrogen-containing 
oral contraceptives show a slight rise in blood pressure (35). 
Malignant hypertension is rare (36), but 5-15S of users can 
expect to become hypertensive. This prevalence is about twice 
that of women of the same age who are not taking an oral 
contraceptive. Many epidemiological studies utilising large 
populations have show that the height of systolic blood pressure 
is a potent predictor of subsequent cardiovascular disease (37). 
Further, actuarial studies indicate that the blood pressure most 
favouring longevity and low morbidity is the very lowest 
compatible with proper circulatory function. Observations of 
this type may explain the excess of deaths from non-rheumatic 
heart disease and cerebrovascular disease seen, particularly in 
older women ingesting oral contraceptives (38).
Secondly, oestrogen3 are known to influence elements of the 
intrarenal hormonal complex previously mentioned - particlarly 
the renin-angiotensin system. Oestrogens have been shown to
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exert a variable effect on thia system, the most consistent 
finding being an increase in plasma renin substrate concentration 
(39). Leas consistent are the reports that oestrogens cause an 
increase in plasma renin activity (40 ). Thus the net effect of 
oestrogen on the renin-angiotensin system is stimulatory, 
resulting in increased levels of angiotensin.il (4a). The few 
reports available concerning oestrogens and the kallikrein-kinin 
system indicate that both kallikrein (42) and kininogen (43) 
concentrations may rise as a result of oestrogen treatsient. 
Similarly, a number of studies have shown that oestrogen can 
stimulate the synthesis of prostaglandins from both vascular 
tissue (44, 45) and the kidney (46). Thus, as for the 
renin-angiotensin system, oestrogen may exert a stimulatory 
effect on both the kallikrein-kinin system and prostaglandin 
synthesis.
The third sphere of research to suggest that oestrogen may 
influence the renal circulation is that of smooth muscle receptor 
physiology. Oestrogens have been shown to alter smooth muscle 
sensitivity to a number of vasoactive compounds by modulating 
receptor physiology. For example, oestrogen can enhance the 
sensitivity of uterine tissue to angiotensin II (47), 
catecholamines (48) and Oxytocin (49), not via a greater affinity 
of uterine receptors for their respective hormones, but through 
an increase in the actual number of these receptors. The 
application of similar studies to the renal vasculature is at 
present beyond the current state of technical expertise. Recent 
work in our own laboratories, however, which has demonstrated 
that oestrogen can increase the number of angiotensin II 
receptors present in the glomeruli of normotensive rats (A.Messenger: 
personal com.)is in agreement with the 'uterine' studies.
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Finally, a clinical, histological and angiographic atudy by 
Boyd et al(50), demonstrated the occurrence of impaired renal 
function, including renal failure, associated with intrarenal 
vascular lesions, in women taking an oestrogen-containing 
compound.
1>5 PURPOSE OF INVESTIGATION
Control of the renal circulation is critical to both normal 
renal function and overall cardiovascular homeostasis.
Intrarenal vasoactive compounds are clearly involved in thia 
control, although the precise nature of their involvement ia not 
clear. A growing body of evidence now exists to suggest that 
oestrogens may exert a powerful influence on the renal 
circulation. Yet, in spite of this evidence, the influence of 
oestrogen on the renal circulation has received only minimal 
attention. Such studies that exist, lack the cohesive approach 
of baking haemodynamic measurements under controlled 
physiological conditions, in conjunction with measurements of 
relevant hormone and enzyme systems at tissue as well as at 
plasma levels.
The objective of this study therefore, was to study the 
influence of oestrogen on both renal and systemic haemodynamics, 
intrarenal vasoactive compounds, particularly angiotensin II, and 
plasma volume status. By adopting this multifaceted approach, 
any relationship between changes in renal and systemic 
haemodynamics may be elucidated, and equated to changes in both 
intrarenal vasoactive compounds and plasma volume.
Studies of this nature, involving invasive surgery and 
tissue measurements, are not possible in humans for ethical 
reasons. The most appropriate animal model must therefore be
\
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used which in this esse is generally held to be the pure-bred 
strains of normotensive end spontaneously hypertensive female 
rats. By studying both strains, it may be possible to firstly, 
achieve a better understanding of the impact of oestrogen on the 
renal circulation, and secondly, to identify differences in the 
circulatory and hormonal responses to oestrogen treatment between 
normotensive models and those animals with underlying 'essential 
hypertension'.
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2.1 INTRODUCTION
The basic Methods used throughout this investigation are 
described. These include a description of the application of 
radioactive Microspheres and radioimmunoassay to measure 
variables of systemic and renal haemodynamics and the 
renin-angiotensin system.
2.2 ANIMALS
Adult female rats have been used throughout the study. 
Sprage-Dewley rats (Nottingham University) were used in the 
studies detailed in chapters 3-5&B. The spontaneously 
hypertensive strain of rat (SHR) and its normotensive Uistar 
counterpart (Olac Ltd, England) were used in the studies described 
in chapteis 6,7.The experimental groups of animals used within 
each study have been age-matched.
Animals were housed at 21 ♦ 1°C, and unless otherwise 
stated, fed with special Diet Services (England) rat and mouse 
number 3 pellets (Sodium content = 0.342, Potassium content =
0.742) and allowed free access to tap water.
2.3 CONDITIONS OF STUDY
2.3.1 Oestrogen Administration
The natural oestrogen oestrone has been used 
throughout the study. Oestrone Acetate (Roussel 
Laboratories Ltd, England) dissolved in ethyl oleate (4 mg 
per ml) was administered by subcutaneous injection.
Control animals received an appropriate injection of 
vehicle alone. Animals destined for either oestrogen or 
vehicle treatment were selected randomly, without bias. 
Likewise, animals were randomly selected into the various 
experimental protocols described in this investigation.
The doses of oestrone used during this investigation
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were selected on the basis of the report of Laslo, F.A.
(51). This detailed study was designed, in part, to 
identify the dose of oestrone likely to influence renal 
vascular aenaitivity to vasoactive compounds.
2.3.2 Anaesthesia
Haemodynamic measurements and tissue sampling as 
performed during thia investigation involvs invasive 
surgery and therefore, the use of an anaesthetic agent to 
induce a surgical plane of anaesthesia. The induction of 
anaesthesia however, has important implications regarding 
these procedures. Firstly, the use of an anaesthetic 
agent can result in cardiovascular instability from, for 
example, hypotension, brachycardia or a fall in cardiac 
output (52). In addition, the use of a barbiturate 
anaesthetic has been shown to cause a fall in renal blood 
flow, both in the rat (53) and dog (5A). Secondly, 
induction of anaesthesia and induction of renin release 
are simultaneous events in the rat (55). Taking
measuramenta from the calm,awake a n imal#post-operatively
would preclude the occurrence of these undesirable events
(56). The necessity of a long post-operative recovery
period would, however, entail a prolonged period of
discomfort for the animal, and would also introduce a real
risk of infection. Further, radioactive microspherea are
unsuitable for use in this scenario.
For the purpose of this investigation therefore, 
haemodynamic measur ements and tissue samples were taken 
from anaesthetised animals. The inhalation agent,
Methoxyf luorane ( Penthrane, Abbott Labs • Lta .
England) was chosen, as this agent is claimed to exert a
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Minimal disturbance on both cadiovascular stability 
(manufacturer's claim) and renin release (55), and ia 
suitable for the induction of a light plane of 
anaesthesia. It is clear however, that the results of 
this investigation must be interpretated in the light of 
the stressful and traumatic event, surgery, and in the 
context of a possible influence of anaesthesia on both 
renal and systemic haemodynamics and the renin-angiotensin 
system (see appendix)«
2.4 VARIABLES >CASURED
2.4.1 Blood Pressure
Blood pressure may be measured by both direct and 
indirect methods in the rat. The direct method involves 
the invasive approach of arterial catheterisation - 
usually of the carotid artery. The implanted catheter is 
connected to a pressure transducer, and recordings are 
made using a polygraph (57). All indirect methods use an 
occlusive device and a procedure for detection of arterial 
pressure when the applied pressure drops below systolic 
and diastolic levels. The tail cuff technique is the 
recognised indirect method for use in the rat (58).
Heating of the animal is required in order to vasodilate 
the tail artery - a thermoregulatory organ in the rat.
Only the dilated tail artery can be used for blood 
pressure measurement.
The advantages of arterial catheterisation are that 
accurate actual aortic pressures can be measured, both 
systolic and diastolic pressures are available, and the 
rapid evaluation of instant changes and continuous 
monitoring are feasible. The main advantages of the tail
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cuff method are that measurements are easily repeatable 
for long periods, and that the technique is non-invasive. 
Whilst the main disadvantages of arterial catheterisation 
apply to long term usage of the technique (and therefore, 
not to this study), the tail cuff method has a number of 
inherent drawbacks. These disadvantages include the need 
to increase body temperature to levels which affect blood 
pressure in normal aniaials (further, spontaneously 
hypertensive rats are more heat susceptible than their 
normotensive counterparts). Thus the procedure has to 
overcosie the instability of blood pressure during the 
warming, and the stress of the animal. Tail cuff size 
also influences blood pressure, as does the position of 
the cuff in relation to the root of the tail; due to the 
existence of a pressure gradient along the tail artery.
Based on the above considerations, the direct method 
appears both store accurate and reliable than the indirect 
method. further, arterial catheterisation is central to 
the technique used to measure cardiac output and renal 
blood flow throughout thia investigation. Arterial 
catheterisation was therefore adopted to measure blood 
pressure. It must be stressed however, that in spite of 
its apparent disadvantages, blood pressure as measured by 
the tail cuff method shows an excellent correlation with 
values obtained by arterial catheterisation over a wide 
range of blood pressure values (Indirect pressure - 0.83 x 
direct pressure ♦ 14.7. r * 0.94, p <  0.001 - unpublished 
data).
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2.4.2 Measurement of cardiac output and renal blood flow
Background
In non-primates, the aorta or renal artery may be 
catheterised, and cardiac output or renal blood flow 
measured directly by any type of flow meter. Similarly, 
an electromagnetic or ultrasonic flowseter may be placed 
on the aorta or renal artery to measure these variables. 
However, indirect methods which do not require major 
surgery sre preferable. The majority of these methods 
utilise the fick principle. This principle, which states 
that mass is conserved in the circulation, and that mass 
is equal to volume multiplied by concentration, enables 
the prediction that the mass of an indicator injected into 
the circulation is equal to its concentration in the blood 
multiplied by blood volume.
A simple example of the evaluation of cardiac output 
using the fick principle is illustrated in fig.2.1. 200
ml of oxygen per minute are absorbed from the lungs into 
the pulmonary circulation, which can carry 40 ml of this 
oxygen per 1 of blood. It follows therefore, that 5 1 of 
blood must have flowed through the lungs per minute to 
pick up 200 ml of oxygen. This 5 1 is a measure of 
cardiac output, its derivation serving to illustrate one 
of the several ways by which cardiac output and regional 
flow may be measured using the fick principle. Generally 
speaking, these procedures involve the introduction of an 
indicator substance, usually either a dye or radiolabelled 
tracer, into the circulation (in the above example, oxygen 
was used). A complex array of equipment is required to
P ULM O NA RY 
A R T E R Y  
(0 ,1 *  160ml/I
VEIN
[0 ,J=  200ml/I
F ig u re  2 .1 Application of the Fick principle  
to measure cardiac ou tpu t. 
(R e fer to te x t)
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measure the concentration/activity of the indicator in 
either blood or tissues. Reliable and accurate 
estimations of cardiac output can be obtained in this way. 
When applied to measure regional flow however, theoretical 
and technical difficulties are often encountered, and the 
validity of values obtained under such circumstances must 
be seriously doubted.
The use of radiolabelled microspheres to measure 
regional flow ia a simple and reliable alternative, irfiich 
overcomes the difficulties previously mentioned, and 
allows the simultaneous measurement of both cardiac output 
and regional flow (59). The technique is again an 
adaptation of the Pick principle. A suspension of 
radiolabelled microspheres is injected into the left 
atrium or ventricle of the heart. Here, the microapheres 
become evenly mixed with the blood and travel with the 
blood to all organs of the body, where they become 
impacted in tissue capillary beds. The number of 
microspheres trapped in an organ will be representative of 
the blood flow to that particular organ according to the 
Fick principlei 
Thus:
q .  r .  |  C ( t ) . d t .  ----------------  1
and: °
Q = CO. J C(t).dt. -------- 2
where:
q = The number of microspheres trapped in the organ 
f = Blood flow to the organ - (ml per min)
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C * The concentration of aicrospheres in the blood - 
(particles per al)
Q = The number of microepheres injected 
CO * Cardiac output - (ml per ain)
By dividing 1 by 2 mo obtain«
q * f  or CO = Q x f . J
Q CO q
As the number of aicrospheres is proportional to 
radioactivity, Q and q can be expressed in counts per unit 
of time. Thus Q/q for a particular organ ia found by 
counting both the radioactivity injected and that present 
in the organ, using an appropriate counter. To determine 
cardiac output, the blood flow to and radioactivity of an 
organ must be known. In practice, a small artery is 
catheterised, allowing blood to flow into a collecting 
chamber as required. This chamber acts as a 'reference 
organ', the blood flow to which can be measured directly. 
This so-called reference blood sample thus enables the 
calculation of cardiac output. The blood flow to a 
particular organ can now be calculated using a 
modification of equation 3«
Organ blood flow (al per ain) s Organ counts x Reference
Reference blood Sample flow 
Sample counts
Before this reference sample microsphere technique can be 
considered valid for the measurement of cardiac output and 
regional flow, several important criteria must be met.
firstly, microspheres must be evenly distributed in 
the blood and have a similar rheology to red blood cells. 
Injection of microspheres into the left side of the
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heart ensures adequate Mixing of blood and aicrospheres 
(60) - provided enough nicrospherea are injectad (61). 
Microspheres have a siailar specific gravity to blood 
(1.50 v. 1.05 g cm ”3 ), and shoe no evidence of 
sediMentation in the circulation (62). In addition, there 
Must be no axial strewing; that is, microapherea oust not 
selectively enter arteries of different diameter. Phibbs 
et al (62), using the rabbit showed that whilst axial 
stressing of Microspheres occurred with large spheres, no 
stressing was present when ssaller 10 pm spheres were 
used. This study also illustrates the iMportance of the 
upper Halt of sicrosphere size in relation to species 
under study.
Secondly, sicrospheres with their suspending Medium 
must not in any way alter haemodynamics. Several studies 
covering a range of species have shown that repeated 
injections of microspheres do not influence either blood 
pressure or organ blood flow (63,64), indicating that the 
injection of microspheres does not effect cardiovascular 
homeostasis.
Thirdly, all microspheres must become impacted in 
capillary beds on their first transit of the circulstion, 
and must not recirculate. Sasaki and Wagner (63), 
measured the extraction efficiency of 50 pm microspheres 
from the pulmonary and systemic circulations of the rat. 
When injected intravenously, 100 S of microspheres were 
trapped in the lungs. When injected into the abdominal 
aorta, 99.6 S were trapped by systemic capillary 
beds, with 0.4 S found in the lungs. The lungs 
therefore, appear to be a reliable indicator of the
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degree of recirculation of microspheres, provided the 
blood supply to the lungs is taken into account. Based on 
this finding, both 50 and 15 pa microspheres have been 
shown to show negligible recirculation in the rat (63,64). 
For studies on the rat, the use of smaller diameter 
microspheres (15 pm) is advocated, as microspheres of this 
siza are less prone to axial streaming, show a good 
rheology to red blood cells, occlude less of the vascular 
bed and are less variable in size. More microspheres can 
therefore be injected, allowing more reliable measurements 
of flow to smaller regions.
The use of radioactive microspheres for haemodynamic 
studies has been the subject of numerous searching 
investigations, some of which have been mentioned here. 
Taken together, these studies indicate that microspheres 
can be used to give reliable and accurate measurements of 
cardiac output and regional flow in the rat. Further, 
aside from being both theoretically and practically sound, 
the use of microspheres in haemodynamic studies confers 
several advantages over the other techniques previously 
mentioned.
Firstly, the ideal indicator for measuring the 
distribution of cardiac output is one with an extraction 
ratio of^1.0 (65). Microspheres conform to this 
description as they do not recirculate. Thus provided 
that the aforementioned criteria are stringently met, the 
technique is accurate, and errors resulting from the 
analysis of dye curves and from indicator loss are 
eliminated. Secondly, the technique is relatively
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undemanding technically; a simple peripheral arterial 
catheter replaces complicated and expensive dye analysis 
equipment. Thirdly, high quality microspheres of 
different sizes with different radiolabels are readily 
available, thus enabling repeated haemodynamic 
measurements to be made in a single animal (66).
When adapted to the rat however, miniaturisation of 
the procedure demands that a high level of precision be 
maintained to avoid the possibility of inducing cardiac 
instability at the critical sioment. If a consistant 
approach is maintained however, reliable and reproducable 
haemodynamic data can be expected when using the rat. 
Surgical Preparation of Animals
Animals were lightly anaesthetised with 
Hethoxyfluoran« (Penthrsne, Abbott Laborstories UK) and 
weighed. The right carotid and left femoral arteries were 
exposed for catheterisstion. The carotid artery was freed 
from surrounding tissue and nerves for s length of 
approximately 1.5 cm by careful dissection. A ligature 
was placed around each end of the isolated section of 
srtery. The distsl ligsture was tied, and the proximal 
ligature used to occlude the artery by tension; both 
procedures preventing subsequent leakage of blood. With 
the artery under tension a small incision - not greater 
than a third of the carotid diameter - was made on the 
anterior face of the vessel, near the distal end of the 
artery. A polythene catheter (outer diameter - 0.75 mm: 
Portex, England) filled with heparinised saline (100 units 
per ml) was carefully inserted 1 cm into the artery and 
secured in place by means of a third ligature.
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The tension on the srtery wee releesed by removing the 
proximal ligeture. The remorel ertery was catheterised 
with a polythene catheter (outer diameter - 0.63 mu) in a 
similar fashion.
Mean arterial pressure (mm Hg) and heart rate (beats 
per min) were measured by means of thg right carotid 
catheter and displayed on an Elcoaiatic (Glasgow, Scotland) 
EM 720 recorder via a Gould (UK) p 323 ID pressure 
transducer. The carotid catheter was passed retrogradely 
into the left ventricle for the injection of radiolabelled 
microspheres: its position being confirmed on the 
Elcomatic EM 720 recorder. The femoral catheter was used 
to collect a reference sample of blood by free flow. Body 
temperature was maintained at 37-38 °C throughout surgery 
with the aid of an Animal Thermopad and rectal thermometer 
(International Market Supply, England).
Determination of cardiac output, renal blood flow and 
vascular resistance
A 1 ml plastic syringe was used to hold approximately 
5 x 10* 141 Ce microspheres (15 pm diameter, 10 mCi per g 
- New England Nuclear, UK) suspended in 0.5 ml of a 0.01 X 
Tween 80 in 0.9 S saline solution.
The radioactivity within the syringe was counted 
using a Wilj (England) 2001 gamma counter. The syringe 
was vigorously shaken for 2 minutes prior to injection 
using a whirlimixer (Fisons, England), and the 
microspheres injected manually over 10 seconds via the 
carotid catheter into the left ventricle. The residual
radioactivity within the syringe was counted and the 
injected radioactivity calculated. Collection of the 
reference blood sample commenced immediately prior to 
injection of microspheres and continued for 60 seconds.
The weight and radioactivity of the reference blood sample
Animals were killed by exaangulnation; blood being 
collected for measurement of the renin-engiotenain system 
and determination of the packed cell volusie, as described 
elsewhere in this thesis. Immediately after death, both 
kidneys were carefully dissected from surrounding tissues, 
removed, weighed and quickly transferred to counting tubes 
for the measurement of radioactivity.
Calculations
Cardiac output (ml per min) was computed asi
Counts Injected
Counts in Reference 
blood sample
x Reference sample blood flow - ml per min 
(weight of blood collected per min ♦ 
density of blood - 1.107 g per ml)
Renal blood flow (ml per min) was computed as:
Total kidney counts x Reference sample blood flow - ml per min 
Counts in reference 
blood sample
Vascular resistance and stroke volume were derived as 
follows:
Total Peripheral Resistance = Mean arterial Pressure 
Cardiac output
Renal vascular resistance = Mean arterial pressure 
Renal blood flow
The unit of resistance used was dyn cm s~l’ (1mm Hg = 
1353.2239 dyn cm ' 2 )
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Stroke volume * Cardiac Output 
Heart rata
All valuea were related to either body or kidney weight as 
appropriate.
2.4.3 Measurements of the Renin Anqiotenein Syateai 
Background
Advances in understanding the renin-angiotensin 
system have quite often resulted from an advance in 
measurement. The first attempt at standardisation of 
assay took place in Goldblatt'a laboratory* with the 
definition of the renin unit. The Goldblatt unit was 
defined as the amount of enzyme necessary to raise the 
blood pressure of a dog of certain weight by 30 mm Hg. 
Biological assays of this type, in which the end point is 
either a rise in blood pressure in the intact animal or 
the contraction of smooth muscle in an isolated organ, 
formed the basis of renin and angiotensin measurements 
until the development of the technique of 
radioimmunoassay. This revolutionised assay methods in 
that it allowed for widespread standardisation, offered an 
increased degree of precision, and allowed measurements to 
be made from small volumes of plasma (important when 
studying small mammals such as the rat).
Measurements of the renin-angiotensin system, using a 
radioimmunoassay comprise two main stages. Firstly, the 
specimen to be analysed (either plasma or renin-containing 
tissue) is incubated, at both temperature and pH optimums 
for renin, in the presence of inhibitors to both
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angiotensin converting enzyme and angiotensinases. These 
inhibitors prevent the loss of angiotensin I to 
measurement, through its conversion to the 
non-cross-reactive angiotensin II, and through enzyaiatic 
degradation, respectively. Secondly, the angiotensin I 
generated from the above incubation is quantitated by 
radioimmunoassay.
Modifications in the incubate from the first stage 
allows the simultaneous measurement of the 
renin-angiotensin variables of interest to this 
investigation - through the radioimmunoassay of 
angiotensin I.
These variables are namelyi 
Plasma Renin Substrate Concentration - Amount of 
angiotensin generated after the addition of excess 
exogenous renin.
Plasma Renin Activity - Amount of angiotensin generated in 
plasma alone, thereby reflecting the endogenous 
concentrations of renin and its substrate.
Plasma and Renal Renin Concentration - Reflects the 
enzymatic activity of renin after the addition of an 
excess of exogenous renin substrate, thus allowing the 
measurement of renin activity independently of variations 
in renin substrate.
It is not the province of this section to review the 
general method of radioimmunoassay. A detailed discussion 
of the principle may be found in Homey and Haber (67 ). In 
brief, the method depends on perturbing the equilibrium
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between a labelled antigen and a specific antibody by the 
unknown antigen to be measured. The antibody used should 
have an equal affinity for the labelled and unknown 
antigen. The antibody must be of sufficiently high 
affinity for measurement of picomolar concentrations of 
the peptide, and of sufficient specificity so that there 
is no cross reaction with other plasma components, 
particularly angiotensinogen (renin substrate). The 
labelled antigen must be highly purified, and must have 
undergone radiolabelling without any impairment of its 
antibody binding properties.
In practice, the unknown antigen is the angiotensin I 
generated from the first stage of the procedure, whose 
radioimnunoassay can be described by the following 
equation:
Angl
(Standard or endogenous)
I - Ang I
ANTIGEN ANTIBODY ANTIGEN-ANTIBODYCOMPLEX
The unknown and I-labelled angiotensin I compete for 
a limited number of antibody binding sites. As the 
concentration of one antigen increases, the fraction of 
the other antigen bound to the antibody decreases. The 
amount of labelled angiotensin I bound to the antibody is 
therefore inversely related to the concentration of 
angiotensin I in the unknown or standard, and serves as an 
index of angiotensin I concentration. This 
antigen-antibody complex can be separated from unbound 
labelled antigen using a number of procedures. The 
radioactivity of either free or bound antigen is counted, 
from which the concentration of angiotensin I in the 
unknown or standard may be calculated. In this fashion, 
using known amounts of angiotensin I, a standard curve is 
contructed, from which the concentration of angiotensin I 
in unknown specimens is found.
Materials
All laboratory chemicals were obtained from either BDH 
(England) or Sigma (UK), unless otherwise stated.
Buffers
Made up in distilled deionised water and stored at 4°C. 
Incubation Buffer
0.12 mol per 1 disodium hydrogen orthophosphate with 0.015 
mol per 1 ethylenediaminetetra-acetic acid (EDTAs 
disodium salt), adjusted to pH 6.5 with sodium dihydrogen 
orthophosphate.
Tissue Homogenisation Buffer
0.1 mol per 1 sodium chloride, 0.05 mol per 1 disodium 
hydrogen orthophosphate, 5 mmol per 1 Na2EDTA, 5 mmol per 
1 8-hydroxyquinoline and 2 mmol per 1
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phenylmethylsulphonyl fluoride (from a stock solution of 
SO mmol per 1 ethanol); adjusted to pH 7.5 with sodium 
dihydrogen orthophosphate.
The Naj EDTA was dissolved in the minimum amount of water 
necessary and the 8-hydroxyquinoline added. Add PMSF and 
previously prepared phosphate buffer dropwise, with 
continual stirring, and heat if necessary. 
Radioimmunoassay Buffer
0.1 mol trizma base with 3 g bovine serum albumin and 2 g 
neomycin sulphate (Biorex Laboratories Ltd, London) per 
litre, adjusted to pH 7.5 with glacial acetic acid. 
Angiotensin Converting Enzyme Inhibitor and Anticoagulant 
EOTA - dipotassium salt.
Ant i-angiotensinases
8-hydroxyquinoline (8-OHQ), phenylmethylsulphonyl fluoride 
(PMSF)and 2,3 - dimercaptopropanol (British Anti-Lewisite: 
BAL). Inhibitors were dissolved in ethanol in the 
required combinations, to give a final concentration of 
inhibitor in plasma.
Angiotensin I Standards
A 9 pg vial of medical research standard A, 71/328 for 
angiotensin I (asp* leu5) synthetic (National Institute 
for Biological Standards and Control, London) was used to 
produce eight standards of 400, 200, 100, 50, 25, 12.5, 
6.25 and 3.125 pg angiotensin I per 200 pi 
radioimmunoassay buffer, by serial dilution. Standards 
were dispensed into plastic assay tubes in 200 pi 
aliquots, capped and stored at -20°C.
Labelled Angiotensin I
10 pCi (3-[***I] iodotyrosyl* ) angiotensin I (2000 Ci per 
mmol - Amersham, UK) mas diluted in radioimmunoassay 
buffer to give approximately 75 x 10* counts per minute 
(cpm) per ml, at the quoted reference date. 2 ml aliquots 
of this diluent were stored at -20°C. On the day of 
assay, the required number of aliquots were diluted lt5 in 
radioimmunoassay buffer to give 15 x 10* cpm per 100 pi. 
Angiotensin I Antibody
1 ml vials of rabbit angiotensin 1 antiserum (New England 
Nuclear, UK) were stored at 4°C. On the day of assay the 
required number of vials were each diluted to 45 ml with 
radioimmunoassay buffer.
Dextran-Coated Charcoal Suspension
3 g charcoal (Hopkin and Williams, England) and 2.5 g 
dextran T-70 (Pharmacia Fine Chemicals, UK) per litre 
distilled deionised water.
Renin Substrate
Nephrectomised rat plasma is a rich source of renin 
substrate, and has a negligible renin activity (68).
Large adult male Sprague-Dawley rats (*'*350g) were 
bilaterally nephrectomised under Methoxyfluorane 
anaesthesia. 18-24 hours post-nephrectomy animals were 
reanaesthetised, and 6-8 ml blood withdrawn from each rat 
by cardiac puncture. Blood was taken into plastic 
syringes - containing 0.05 volume of a 100 g per 1 
solution of K2EDTA, and pooled in a plastic receptacle 
placed on ice.
Blood was centrifuged at 3000 rpm for 10 minutes at 4°C.
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Plasma was decanted off and placed in viaking dialysis 
tubing (Scientific Industries Internatiorv Inc., UK). Sacs 
were dialysed against ~  SO volumes of incubation buffer pH 
6.5, for 17 hours at 4°C. Renin substrate rich plasma was 
stored in 100 pi aliquots at -20^C.
Renin
Purified renin extract mas obtained from bovine renal 
tissue. Tmo fresh com kidneys Mere obtained from a local 
slaughterhouse, chilled, and stored at -2fPC. Renin mbs 
extracted and purified from thamed outer cortex lobes 
after the method of Haas, et al (procedure A) (69), 
Purified renin extract m s s  stored in 100 p i  aliquots at 
-2(f C.
Methods
Unless othermise stated, all procedures Mere carried 
out at 4 %, using plastic, standard 3 ml assay tubes 
(Luckhams, UK), Mhich Mere shaken Mith a Whirlimixer 
(Fisons, England) after each addition.
Stage I - Generation of Angiotensin I.
All incubations Mere performed in a materbath 
(Gallenkamp, UK) at 37^C. Reactions Mere stopped by 
plunging incubates into ice-cold Mater.
Plasma Renin
Immediately after collection, blood used to measure 
plasma renin activity, concentration and substrate 
concentration (approximately 3 ml) Mas added to EDTA (10:1 
volume of a 100 g per 1 solution of the dipotassium salt), 
chilled and centrifuged at 3000 rpm for 10 minutes.
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Plasma was decanted off and stored at -20°C until 
required.
On the day of assay, samples were allowed to thaw 
slowly on ice. for each plasma, renin activity, 
concentration and substrate concentration were measured 
from the same assay - to eliminate variations which may 
result from repeated freezing and thawing of plasma (70). 
Plaaaia Renin Activity
250 pi plasma was added to an equal volume of 
incubation buffer. 5 pi anti-angiotensinaae cocktail was 
added, containing PMSF and BAL, to give a final 
concentration of inhibitor in plasma of 1 and 4.7 mmol per 
1 respectively. The 505 pi incubate was split into three 
equal portions, which were incubated in capped assay tubes 
for 0, 20 and 30 minutes respectively. 10 pi of each 
incubate was used for radioimmunoassay of angiotensin I as 
described in Stage 2.
Plasma Renin Concentration
5 pi PMSF/BAL cocktail (final concentrations in 
plasma: 1 and 4.7 m mol per 1 respectively) was added to 
100 pi binephrectomised rat plasma. Add 25 pi plasma and 
buffer with 125 pi incubation buffer. The 255 pi incubate 
was split and incubated as for plasma renin activity. 
Similarly, 10 pi of each incubate was used for stage 2. 
Plasma Renin Substrate Concentration
300 pi incubation buffer, containing 8-OHQ (final 
concentration in plasma: 17 mmol per 1), was added to 100 
pi bovine renin extract. 160 pi of this mixture was added 
to 40 pi plasma. 80 pi portions of the incubate
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were incubated for 0 and 60 minutes.
80 |il of a 10 X solution of trichloroacetic acid Mas 
added to each incubate, Mhich Mere then centrifuged at 
3000 rpm for 5 Minutes. 80 pi supernatant mss added to 
1,420 pi of a Mixture of radioiMMunoaesay buffer (30 ml) 
and 1 M sodium hydroxide (1.116 ml). 200 pi of this 
mixture mbs assayed in stage 2.
Renal Renin Concentration
Renal cortsx (approximately 50 mg) mss frozen 
immediately after removal, and stored at -20PC prior to 
measurement of renal renin concentration. Cortex samples 
Mere homogenised in homogenisation buffer (10 mg cortex 
per ml buffer), using 10 ml glass homogenisstion tubes 
and teflon pestles (Scientific Industries International 
Inc. (UK) ) and a Tri-R K41 homogeniser. The homogeniser 
Mas set at half speed, and 3 x 10 second passes used to 
effect homogenisation. Homogenates Mere transferred to 20 
ml plastic tubes (Sterilin, England) and centrifuged at 
3000 rpm for 10 minutes to remove tissue debris.
Supernatants Mere decanted off, and 200 pi samples of each 
supernatant stored at -20°C, for measurement of protein 
content at a future date.
5 pi PMSE/8-0HQ cocktail (final concentrations in 
supernatant: 1 and 5 mmol per 1 respectively) Mas added to 
100 pi binephrectomised rat plasma. 10 pi supernatant Mas 
added to the mixture. The 115 pi incubate mas split into 
three portions Mhich Mere incubated for 0, 15 and 30 
minutes respectively.
15 and 30 minute incubates Mere diluted either x 20 
or x 50, as required rnith radioimmunoassay buffer. 10 pi
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of each incubate mbs used for stage 2,
Stage 2 - Radioimmunoassay of angiotensin I
Assays were performed using duplicates of each 
determination.
Assay tubes 1-24 enable a standard curve to be 
constructed.
Tubes 1-3 contain 400 pi radioimmunoassay buffer and 
100 pi labelled angiotensin I - TOTALS.
Tubes 4-5 contain 200 pi radioimmunoassay buffer and 
200 pi angiotensin I antibody. Here, there is no antibody 
to bind specifically to the antigen (angiotensin I). 
Instead, antibody will bind non-specifically to the walls 
of the tube, separation agent, etc - BLANK.
Tubes 6-8 contain 200 pi radioimmunoassay buffer, 200 
pi angiotensin I antibody and 100 pi labelled angiotensin
I. Here, there is no competition between labelled and 
unlabelled antigen. The concentration of unlabelled 
antigen is zero and the maximum amount of labelled antigen 
will be bound - Bo.
Tubes 9-24 contain the eight unlabelled angiotensin I 
standards, in increasing concentrations, 200 pi 
angiotensin I antibody and 100 pi labelled angiotensin I - 
STANDARDS.
Tubes 25 onwards contain the appropriate volume of 
unknown plasma or renal cortex supernatant, (Volumes were 
calculated so as to ensure that the amount of angiotensin 
I generated from Stage I was within the working range of 
the standard curve), 200 pi radioimmunoassay buffer, 200 
pi angiotensin I antibody and 100 pi labelled angiotensin
I - UNKNOWNS.
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Assay tubes were allowed to incubate for 
approximately 15 hours prior to separation of bound and 
unbound fractions.
Separation Procedure
1 ml of stirred dextran-coated charcoal suspension 
was added to each assay tube. Within 5 minutes, tubea 
were centrifuged at 3000 rpm for 5 minutes. The bound 
(supernatant) and free (charcoal pellet) fractiona were 
separated by aspiration, using a vacuum pump, and the 
radioactivity of the charcoal pellet counted in either a 
Wilj 2001 or LKB (England) Clini Gamma gamma counter.
Data Reduction
Data obtained from the counters were analysed using a 
Hewlett Packard (UK) - 97 programmable printing calculator 
and radioimmunoassay programmes.
The radioactivity of TOTALS, BLANK and Bo was used to 
express the radioactivity of STANDARDS as the percentage 
of bound antigen (B) to Bo, that is, B/Bo. For each 
standard, B/Bo was plotted against the logarithm of the 
concentration of the standard. The resultant sigmoidal 
linear-logarithmic curve was transformed into a straight 
line by interpolation, using a logit transformation. The 
formula for transforming B/Bo to the corresponding logit 
is:-
logit (B/Bo) s Ln B
Bo - B
A logit plot in effect, stretches out the flatter 
parts of the sigmoidal B/Bo logarithm concentration plot, 
to create an approximately linear plot - Fig. 2.2.
A least squares regression line on a logit B/Bo - 
logarithm concentration plot was used to fit a straight
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line to the standard curve (71).
The radioactivity of UNKNOWNS was used to calculate a 
concentration of angiotensin I in pg from the standard 
curve.
Renin activity and concentration were expressed as ng 
angiotensin 1 *1“* plasma hour"*, and renin substrate 
concentration aa ng angiotensin 1 per ml plasma. Renal 
renin concentration mss initially expressed as ng 
angiotensin I per hour. Values obtained from UNKNOWNS 
must therefore be converted from pg angiotensin I to the 
appropriate form. The following derivation, using plasma 
renin activity (PRA) as an example, illustrates how this 
was achieved:
i) pg Ang I — * ng Ang I x 103 ----- 1
ii) Ang I per x pi plasma — * Ang I per ml plasma
x * volume of plasma contained within the 10 pi incubate 
used for assay
a 4.95 pi
Therefore:
Ang I per 4.95 pi -- - Ang I per ml x 1000 ----- 2
4.95
iii) Ang I per 20 min - T20
Anq I per hr 3(T20) +■ 2(T30) —  3
Ang I per 30 min - T30
Combining 1,2 and 3 we have:
__1 « 3(T20) . 2(T30) ng Ang I ml'1 hr-
*.95 2
PRA -
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Quality Control
Immunological assays are subject to errors arising 
fro« the instability of reagents and the involvement of 
complex manipulations such as dilution and separation 
stepa (72). Thus it is necesssry to adopt control 
procedures in order that assay performance be maximised 
and then maintained within acceptable limita. This is 
schieved by measuring the precision and reproducibility of 
assays.
Errors in rsdioimmunosssay arise from firstly, sample 
preparation and secondly, the random nature of radioactive 
decay. Preparation error includes errors due to 
pipetting, mixing, incomplete sepsration of bound and free 
fractions, dilutions etc. Further, a large preparation 
error in duplicates may effect the fitting of the standard 
curve and therefore, the evaluation of the whole assay.
The precision of assays was evaluated by the 
inclusion of control samples in the assay procedure, which 
permitted the measurement of both intra- and inter-assay 
variation. Intra-assay variation was measured by the 
addition (to stage 1) and subsequent recovery (from stage 
2) of known amounts of angiotensin I. By adopting this 
procedure, intra-assay variation was 104 + B (mean ♦ SEN : 
n s 7), 100 ♦ 5 (n s 6) and 126 ♦ J S (ns 3), for plasma 
renin activity, concentration and substrate concentration 
assays, respectively. Inter-assay variation was measured 
from control samples of either pooled plasma or pooled 
renal cortex supernatant, which were incubated and assayed as
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for UNKNOWNS. Fro« this procedure, inter-assay 
coefficients of variation were found to be 6.9 % at 52 pg 
angiotensin I (n * 20) and 12.7 * at 56 pg angiotensin I 
(n s 9), for plasma and renal renin assays respectively.
The concentrations of angiotensin I used to assess 
intra- and inter-assay variability were in the working 
range (linear region) of the B/Bo - logarithm 
concentration plot. Further, the generation of 
angiotensin I from stage I incubations showed a linear 
increase with time. This important observation shows the 
efficiency with which anti-angiotensinases prevent the 
loss of angiotensin I to measurement.
The reproducibility of assays was monitored from 
information inherent to the assay procedure, such as data 
from replicates and the standard curve. Values showing an 
obvious deviation from the appropriate replicate (a good 
estimation of preparation error) were discarded. The 
profile of each B/Bo - logarithm concentration plot was 
analysed together with data from each regression line on 
the logit B/Bo - logarithm concentration plot. Assays 
were rejected if either the B/Bo - logarithm concentration 
plot profile deviated from normal, or if the regression 
line on the logit of the above plot yielded a correlation 
coefficient of <  0.999.
2.4.4 Measurement of Protein Concentration 
Background
The measurement of renal renin concentration - from 
homogenised renal cortex samples - has been described in 
the preceding section. Renin concentration was expressed 
as ng angiotensin I generated per hour. Tissue enzyme
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concentrations are however, conventionally related to 
either the weight or protein content of tissue. Due to 
the possibility that renal cortex samples may have become 
dehydrated whilst stored at -20° C  (a view supported by 
the observation of the presence of ice crystals 
surrounding certain specimens), it wa* considered 
inappropriate to relate renal renin to cortex weight. A 
measurement of protein content on the other hand, is 
widely recognised as a mo.e consistent, and therefore 
reliable standard, to which tissue enzymes such as renin, 
may be related. Thus the protein concentration of renal 
cortex homogenates was measured, in order to relate renal 
renin concentration to the protein content of the 
corresponding renal cortex sample.
A preliminary experiment designed to measure the 
protein content of a pooled sample of renal cortex 
homogenate, using the Lowry method (73), clearly indicated 
that the buffer in which cortex samples had been 
homogenised was interfering with the procedure. This 
interference probably resulted from the presence of EDTA 
and 8-hydroxyquinoline in the buffer.
Precipitation of the protein contained in renal 
cortex homogenates by the combined use of sodium 
deoxycholate and trichloroacetic acid, is a convenient 
one-step method of separating protein from interfering 
reagents (74). The precipitated protein can then be 
measured using the standard Lowri method.
Materials
All reagents (made up in distilled deionised water, 
unless otherwise stated) were obtained from either BDH
(England) or Sigma (UK).
Phosphate Buffer. pH 7.S ( see incubation buffer: p32 )
Protein Standards
25 mg bovine serum albumin was dissolved in 25 ml 
phosphate buffer. This stock solution was used to prepare 
eight standards of 1000 , 750 , 500 , 375 , 250, 125, 100 and
0 pg of protein per ml, by dilution in the phoaphate 
buffer.
Precipitation Aoents 
2 % sodium deoxycholate 
20 X trichloroacetic acid 
Reagent A
1 ml 20 g per 1 sodium potassium tartrate 
1 ml 10 g per 1 copper sulphate
Made up to 100 ml with 20 g per 1 sodium carbonate in 0.1N 
sodium hydroxide.
Reagent B
IN Folin-Ciocalteu phenol reagent 
Methods
Unless otherwise stated, all procedures were carried 
out at room temperature in plastic, 4 ml assay tubes 
(Luckhams, UK), which were shaken with a Whirlimixer 
(Fisons, England) after each addition.
On the day of assay, renal cortex homogenates (see p37 ) 
were thawed and diluted 1:5 in phosphate buffer. This 
dilution factor was found to give protein values in the 
working range of the standard curve, when the following 
assay procedure was applied to each sample:
50 pi sample (either standard or diluted renal cortex 
homogenate) was adjusted to 3 ml with distilled deionised
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water. Add 25 pi sodium deoxycholate and allow to atand 
for 15 minutes. 1 ml trichloroacetic acid was added, and 
the mixture centrifuged at 3,500 rpm for 30 minutea. The 
supernatant was removed by aspiration, and 1 ml reagent A 
added to the protein pellet. After 10 minutes, 100 pi 
reagent B was added, and the mixture allowed to stand for 
at least 45 minutas.
After 1 hour, samples were transferred to cuvettes 
(light path:l cm, Sarstedt, UK), and absorbance measured 
at a wavelength of 750 nm, using a CE * CIL (England) 5093 
double beam spectrophotometer.
Oata Reduction
The theory behind folin phenol quantitation of 
protein is well documented (75) and need not be detailed 
here. Briefly, the non-linear relationship between 
protein concentration and absorbance can be accurately 
described by a power function of the formt 
p * (»/•) 1/b
where: P = protein concentration, A = absorbance, and a 
and b are constants.
In practice, a Hewlett Packard (UK) - 97 programmable 
printing calculator and curve fitting programme were used 
to construct the linear absorbance-concentration plot from 
which the protein concentration of renal cortex 
homogenates (pg per ml) was calculated. These values were 
used to equate renal renin concentration (ng angiotensin I 
per hr) to protein content (per mg) as follows!
Using the above procedure lOOOpl cortex homogenate 
was found to contain x uq protein
During stage 1 of the radioimmunoassay procedure used 
to measure renal renin concentration, 10 pi of the above 
homogenate m s s  added to 105 pi of renin aubstrate and 
inhibitora. 10 pi of this mixture was asssyed for 
angiotensin I, and contained _x_ x 10 jig of protein (y ug protein)
This 10 pi was found to have generated » nq anql per hr, 
and therefore contained:
z x 1000 ng ang 1 per mg of renal cortical protein per hr.
y2.4.5 Measurement of Packed Cell Volume
The control of extracellular fluid volume is critical 
to the maintenance of cardiovascular homeostasis. For 
example, acute and severe haemorrhage will induce a fall 
in both arterial pressure and renal blood flow, resulting 
in shock. The renin-angiotensin system plays a central 
role in the control of extracellular fluid volume, 
principally through the stimulatory effect of angiotensin 
II on the sdrenal cortex (aldosterone) (76).
A change in the packed cell volume (haematocrit) of 
blood is widely recognised as s reliable reflection of a 
change in plasma volume (77). A sample of blood was 
therefore taken from each animal as described previously. 
Blood was taken into potassium EOTA, and the packed cell 
volume measured using a coulter S+ analyser.
2.5 Statistics
Data obtained from experimental groups of animals were 
initially tested for normality of distribution. For each 
variable, those data found to be normally distributed were
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pressnted a s  a mean ♦ 95 % confidence limits (eg. 125 ♦ 12) (76). A 
median and range (eg. 6.7s 1-17) were uaed to describe those data 
found to be non-normal ly distributed.
The significance of differences between groups of animals 
was tested using the expedient parametric (one way analysis of 
variance (ANOVA) or paired t-test) or non-parametric 
(Kruskal-Wallis or Wilcoxon rank sum test) test. Where 
appropriate, the relationship between two variables has been 
investigated by means of either a correlation or regression 
analysis (79). The probability value of the respective test 
statistics f, t, H, Z and r has been used to express the level of 
significance of differences or relationships as follows: NS, non 
significant; *, p <  0.05; **, p<0.01; ***, p <  0.001.
Chapter 3
INFLUENCE OF OESTROGEN ON RENAL AND SYSTEMIC HAEMODYNAMICS 
THE RENIN-ANGIOTENSIN SYSTEM AND PLASMA VOLUME STATUS
IN THE NORMOTENSIVE RAT
J.l INTRODUCTION
The kidney ie one of the mein organs concerned with the 
Maintenance of cardiovascular homeostasis. This is schieved by 
several interrelated systems including those involved in 
extracellular fluid volume regulation as well as the production 
and/or activation of vasoactive compounds suçh as angiotensin, 
prostaglandins and kinins. Haemodynamic disturbances, such as 
hypertension, are common to many types of renal disorders. 
However, the mechanisms whereby such disturbances are maintained 
by structural and functional intrarenal changes are poorly 
understood. Likewise, the influence of alterations in systemic 
haemodynamics upon intrarenal autoregulatory mechanisms, 
especially those governing blood flow, remain obscure.
Oestrogen can perturb normal cardiovascular function, as 
evidenced by the occurrence of hypertension in women ingesting 
oestrogen-containing oral contraceptives (5J,J4). Further, it is 
clear that oestrogen may have the capacity to influence the 
control of the renal circulation (see p 11 ). To date however, 
there have been no detailed studies of the role of the renal 
circulation and its control mechanisms in relation to changes in 
systemic haemodynamics during oestrogen treatment.
The objective of this study therefore, was to assess the 
impact of oestrogen on both systemic and renal haemodynamics, the 
renin-angiotensin system and plasma volume status in the rat. By 
studying the archetypal intrarenal hormonal vasopressor system, 
it may be possible to obtain a better understanding of the role 
of the renal circulation in relation to changes in systemic 
haemodynamics during the pharmacological challenge of oestrogen
treatment.
50
3.2 fCTHODS
Adult female Sprague-Dawley rata (Nottinghaa University) 
weighing 190-240g were used throughout the atudy. Animals were 
housed at 21 ♦ 1°C, fed with Special Diet Services (England) rat 
and mouse number 3 pellets (Sodium content: 0.34%: Potassium 
content: 0.74%) and allowed free access to tap water.
Oestrone acetate in ethyl oleata (4 mg per ml) was 
administered by subcutaneous injection to two groups of animals.
Group A received a total of 3 mg oestrogen: given as either 
0.5 mg per day for 10 days, or 1 mg on alternate days for 10 
days. Group B received a total of 10 mg oestrogen: given as 
either 1 mg per day for 10 days, or 1 mg on alternate days for 
20 days. Control animals were given an appropriate injection of 
vehicle alone. All animals were weighed daily whilst receiving 
injections.
24-hours after receiving their last injection of either 
oestrogen or vehicle, animals were prepared for experimental 
analysis. This surgical preparation, together with the 
procedures which were subsequently applied to measure systemic 
and renal haemodynamics, plasma and renal renin, and packed cell 
volume, have been fully described in Chapter 2.
3.3 RESULTS
The injection of vehicle alone did not alter any of the 
parameters under study (Table 3.1). For the purpose of clarity 
therefore, data obtained from vehicle injected animals has been 
pooled, and referred to as the control group against which the 
oestrogen treated groups have been compared. Likewise, data from 
oestrogen treated animals has been presented in relation to the 
total dose of oestrogen administered, since the frequency of 
dosage was found to be irrelevant. Group A therefore relates to
SI
animals mho received a total of $ mg oestrogen, and group B to 
animals who received a total of 10 mg oestrogen.
Haemodynamics (Figure 3.1 and Table 3.2)
Renal Blood Flow (RBF)
Renal Blood Flow fall from a control value of 3.65 ♦ 0.33 ml 
g~lmin_l to 4.71 ♦ 0.41 ml g'lsin'l in group B (p< 0.01), but 
remained unchanged to group A at 3.11 ♦ 0.59 ml g_1min*A.
Mean Arterial Pressure (HAP)
Oestrogen trestment resulted in a rise in MAP from a control 
value of 120 ♦ 2 mm Hg to 129 ♦ 4 (p< 0.001) and 136 ♦ 4 (p <
0.001) mm Hg in groups A and B respectively. The rise in MAP 
induced by oestrogen in group B was significantly larger than 
that noted in group A (p< 0.05).
Cardiac Output (CO)
Values for CO in group A and B were 239 ♦ 24 and 278 ♦ 37 ml 
min-lkg"l respectively. These vslues did not differ 
significantly from that recorded in the control group of animals 
(252 ♦ 16 ml min ”1 kg-1).
Total Peripheral Resistance (TPR)
TPR remained unchanged as s result of oestrogen treatment, 
with values of 39,482 ♦ 2,705, 44,271 ♦ 4,622 and 42,258 ♦ 443 
dyn cm -5 sec -1 kg "1 in controls, group A and group B 
respectively.
Renal Vascular Resistance (RVR)
RVR rose from a control value of 1,764 ♦ 133 dyn cur* se<r* kg'* 
kidney to 2,067 ♦ 127 (p< 0.05) and 2,219 ♦ 267 (p< 0.001) dyn 
crn-5sec-1 kg-1 in groups A and B respectively.
Plasma and Renal Renin (Figure 3.1 and Table 3.2)
Plasma Renin Activity (PRA)
PRA increased from a control value of 8.35 ♦ 1.22 ng Ang I 
ml~lhr~lto 12.67 ♦ 1.59 ng Ang I ml”*hr~*in group B (p<0.001)
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but remained unchanged in group A at 6.97 ¿1.39 ng Ang I el"1hfrl. 
The value for PRA observed in group B was significantly greater 
than that observed in group A (p< 0.001).
Plasma Renin Concentration (PRC)
Oestrogen reduced PRC from s control value of 102.4 ♦ 14.1 
ng Ang I ml"1 h r 1 to 54.3 ♦ 14.3 (p< 0.001) and 33.7 ♦ 4.7 (p <  
0.001) ng Ang I ml-* hr-iin groups A and B respectively. The 
decrease in PRC noted in group B wss significantly greater than 
that noted in group A ( p <  0.01).
Plasma Renin Substrate Concentration (PRS)
PRS increased in the oestrogen treated rat from a control 
value of 230 ±  16 ng Ang I ml-1 to 424 ♦ 69 (p< 0.01) and 610 ♦ 
86 (p <  0.001) ng Ang I ml*1 in groups A and B respectively. The 
rise in PRS noted in group B was significantly greater than that 
noted in group A (p <  0.05).
Renal Renin Concentration (RRC)
Oestrogen reduced RRC from a control value of 10,222 ♦ 1,060 
ng Ang I m g ’* renal cortical protein hr“1 to 6,473 ♦ 1,368 (p< 
0.001) and 5,544 ♦ 770 (p< 0.001) ng Ang I mg”* renal cortical 
protein hr-* in groups A and B respectively. There was no 
difference in RRC between groups A and B.
Packed Cell Volume (PCV)
A fall in the PCV occurred as a result of oestrogen 
treatment, from a control value of 36.7 ♦ 0.6 2 to 33.0 ♦ 1.4 (p <1 
0.001) and 32.5 ¿0.6 2 (p<0.001) in groups A and B 
respectively.
Body Weight
Control animals gained an average of 0.8 g per day (n = 18), 
whereas animals in groups A and B lost 1.35 (n = 17) and 2.1 g 
per day (n = 14) respectively. This loss in body weight induced 
by oestrogen is in agreement with published data (80).
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Relationships Between Oestrogen Induced Changes in Haemodynamics^ 
PRA and PCV
The fall in RBf induced by oestrogen in group B took place 
with einiiaal changea in both CO and TPR, but was accompanied by 
significant rises in RVR, MAP and PRA.
From Figure 3.2 it can be seen that in the oestrogen treated 
animal, the percentage increase in RVR exceeda that in TPR; this 
difference being greatest in group B where the ratio of change in 
RVR to TPR was 5.3il.
Although an inverse correlation between RBF and PRA was 
noted in both controls (RBF x - 0.144.PRA ♦ 6.77; r * - 0.454; n 
* 20; p <  0.02) and group A (RBF = - 0.208.PRA ♦ 6.61; r * - 
0.488; n x 17; p <  0.05), no such relationship was found in group 
B (Fig.3.3).
An inverse correlation was observed between PCV and MAP (PCV * - 
0.107.MAP ♦ 48.7; r a - 0.354; n x 55; p<0.01) when the data 
from all experimental animals were considered together (Fig.3.4). 
No relationship was noted between RBF and MAP in any experimental 
group. Likewise, there was no relationship between MAP and PRA 
in any experimental group.
3.4 DISCUSSION
The findings from this study have demonstrated that whereas 
oestrone acetate, given as a total dose of lOmg, resulted in a 
significant fall in renal blood flow in the normotensive rat, no 
change in renal blood flow occurred with a total dose of 5 mg. 
This effect of oestrogen could not be accounted for by a change 
in cardiac output, but was accompanied by a 37S increase in renal 
vascular resistance. Both oestrogen regimes resulted in a 
significant rise in mean arterial pressure, which was dose 
dependant, and associated with a significant fall in the packed
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cell volume. Whereas both oestrogen regimes resulted in a fall 
in plasma and renal renin concentrations and a rise in plasma 
renin substrate concentration, an increase in plasma renin 
activity was only noted with the higher dose. A loss in body 
weight was noted in both groups of oestrogen treated rats.
Previous reports of the effect of oestrogen on renal 
haemodynamics have indicated that renal blood flow either remains 
unchanged (81-83) or increases slightly (84)i a decrease in renal 
blood flow with oestrogen having not been previoualy reported. 
This disparity between previous reports and the present finding 
may well be due to differences in the nature of the oestrogen 
preparation used, the schedule of administration employed, or the 
species involved.
The fact that the smaller riae in mean arterial pressure 
(seen in animals receiving 5 mg oestrogen) took place without a 
change in renal blood flow, suggests that the oestrogen-induced 
fall in renal blood flow took place as the result of an 
antecedent rise in blood pressure. The lack of any relationship 
between these two haemodynamic variables is not, however, 
consistent with this chronology of events. This finding, coupled 
with the observation that oestrogen-induced increases in renal 
vascular resistance were much greater than changes in total 
peripheral resistance suggests either that the reactivity of the 
intrarenal vasculature -to humoral or neurogenic factors - is 
different from that of the systemic circulation in this 
particular animal model, or that the mechanisms responsible for 
the change in RVR were predominantly intrarenal. Both could be 
mediated by either a direct or indirect influence of the steroid. 
Although the suggestion of a direct intrarenal effect of 
oestrogen may be attractive in the knowledge that specific
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oestrogen receptors ere known to be present in the kidney (05), 
their distribution does not include vascular tissue, thus making 
it unlikaly that oestrogen has a direct effect on renal 
vasculature. On the other hand, there ia abundant evidence to 
support the view that oestrogena may influence intrarenal 
vascular resistance through indirect pathways. This includes the 
observations that oestrogens are known to activate the 
renin-angiotensin system (40), to increase the number of smooth 
muscle angiotensin II receptors (47), to enhance smooth muscle 
sensitivity to catecholamines (48) and vasopressin (49), to exert 
a variable effect on vascular prostaglandin activity (44-46) and 
to influence the kallikrein-kinin system (42,43).
The finding of a correlation between RBf and PRA in control 
and group A animals is consistent with the view that the RAS 
plays a role in the modulation of renal haemodynamics under 
conditions of normal RBf. However, the lack of any such 
relationship in animals with a reduced RBf makes it doubtful that 
the increase in PRA (and therefore, probably circulating 
angiotensin II) noted in these animals played a major role in 
determining the rise in RVR. Thia conclusion requirea further 
consideration if one accepts that the concentration of renin or 
angiotensin II present in the systemic circulation may be a poor 
index of that present in the peripheral arterioles (86,87). One 
might therefore speculate, that under the influence of oestrogen, 
an excessive accumulation of either renin or renin substrate 
occurs in renal resistance vessels, leading to an enhanced 
generation of Ang II locally. The fall in RRC recorded in 
oestrogen treated animals does not necessarily detract from this 
hypothesis, since RRC chiefly reflects renin production and/or 
storage by the juxtaglomerular apparatus and is not
therefore a valid reflection of ita concentration in the renal 
vaaculature itself.
Oestrogen M a y  alao have the capacity to Modulate the 
intrarenal action of angiotenain II, by changing the nuMber 
and/or affinity of intrarenal vaacular angiotenain II receptora.
Support for thia theory nay be derived froM .the observation that 
oestrogen senaitisea the myometrium to the effect of angiotenain 
II through an increase in the number of angiotenain II receptors 
(47). Recent studies in our own laboratory, which have 
demonstrated that oestrogen increases the number of angiotenein 
II receptors in the glomeruli of normotensive rats (A. Messmger: 
personal com)give further support to this idea.
The possibility that the oestrogen-induced fall in RBf might 
also have resulted from the influence of this steroid on either, 
other vasoactive compounds involved in the modulation of renal 
haemodynamics, such as prostaglandins (44-46) or kinins (42,43) 
or a stabilisation effect on cell membranes (88) cannot be 
excluded by this study.
Previous reports on the effect of oestrogen on blood 
pressure in the rat (89,90) are in agreement with the increases 
in mean arterial pressure seen in this study. The level of blood 
pressure in the body is determined by the product of cardiac 
output and total periph eral resistance« The latter two variables 
in turn, are chiefly set by respective changes in extracellular 
fluid volume and the balance of vasoactive compounds. These 
'volume' and 'vasoconstrictor' components usually move in 
opposite directions to maintain a normal level of blood pressure. 
Excessive increases in either cardiac output or total peripheral 
resistance are the respective hall-marks of volume or 
vasoconstrictor mediated hypertension. However, the lack of any
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marked change in either cardiac output or total peripheral 
reaiatance, suggests that the oestrogen-induced increase in mean 
artarial pressure encountered in thia study involved a 
combination of both volume and vasoconstrictor factors.
Given that a reduction in packed cell volume reflects an 
enlargement in plasma volume (77)( the fall in packed cell volume 
noted in both oestrogen treated groups of rats ia consistent with 
the involvement of a prominent volueie component in the 
hypertension encountered in these animals. Powerful support for 
thia hypothesis may be derived from the present abaervati«» of a 
string reciprocal relaticnahip between mean arterial pranre and the packed 
oell volute.
One might have anticipated that the oestrogen-induced 
expansion of plasma volume, described above, would have resulted 
in a decrease in plasma renin activity, rather that the unchanged 
and increased values noted in animals receiving 5 and 10 mg of 
oestrogen respectively. This apparently inconsistent finding may 
be explained by the fact that oestrogen increases the hepatic 
biosynthesis of renin substrate (39) - as confirmed by this 
study. This increase would result in firstly, a rise in 
circulating angiotensin II (detected as an increased plasma renin 
activity) and secondly, a fall in renin secretion (detected as a 
decreased plasma and renal renin concentration) by a direct 
negative feedback pathway. The overall effect of these changes 
in the renin-angiotensin system would be to nullify any 
compensatory fall in total peripheral resistance, which might 
have been expected to occur in response to an increase in plasma 
volume.
On the basis of the above findings, it seems likely that the 
mechanisms leading to the establishment of an
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oestrogen-induced increase in blood pressure, as noted in this 
study, involve a combination of expanded plasma volume, coupled 
with a renin-angiotensin activity which is inappropriately high 
in relation to the volume status of the animal. Moreover, an 
increased plasma volume appears to be the primary event 
responsible for the establishment of the increased blood 
pressure, which may be exacerbated by activation of the 
renin-angiotenain system. Support for this hypothesis may be 
derived from the obaervation that whereas mean arterial pressure 
was inversely related to packed cell volume, it showed no 
relationship to plasma renin activity. Further, an increased 
plasma renin activity was only noted in animals exhibiting the 
larger rise in MAP.
Extracellular fluid volume expansion thus appears to be the 
primary event leading to the establishment of the elevated mean 
arterial pressures seen in this study. This expansion may be 
initiated by sodium retention. The antinatriuretic properties of 
oestrogen have long been recognised (91-93), and may account for 
the oedema seen in some women, both prior to menstruation (94,95) 
and during late pregnancy (96); circumstances when blood 
oestrogen levels are elevated. The site of this property ia 
predominantly intrarenal (though not necessarily mediated through 
the adrenal glands) (97 ), although extrarenal sites have also 
been identified (90 ).
The involvement of the renin-angiotensin system in 
oestrogen-associated hypertension is demonstrated by the report 
of Stubbs et al (99). In this study, the competative angiotensin 
II antagonist (Sar-lAla-6) angiotensin II was infused into rats 
with elevated blood pressure levels through oral contraceptive 
pretreatment (Enovid), and a return of blood pressure to the
59
pretreatment levels noted.
In conclusion, oestrogen has been shown to affect marked 
changes in renal and systemic haemodynamics, the 
renin-angiotensin system and plasma volume status in the 
normotensive rat. A reduction in renal blood flow occurred 
independently of a rise in mean arterial pressure. This 
reduction in renal blood flow could not be accounted for by a 
change in cardiac output, but was due to an increased renal 
vascular resistance in the presence of an elevated plasma renin 
activity. This observation suggests that angiotensin 11-mediated 
vasoconstriction of the renal vasculature was responsible for the 
reduced renal perfusion described above. The rise in mean 
arterial pressure sppeared to be principally determined by salt 
and water retention, in conjunction with a plasma renin activity 
which was inappropriately high in relation to plasma voluite
status.
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4.1 INTRODUCTION
Renin is an acid protease, and as such Might be expected to 
exist in an enzymatically inactive precursor fora. Indeed, other 
members of the same family are synthesised as proenzymes; for 
example - pepsin. Recently, an intracellular prorenin has been 
identified (100, 101) and its amino acid sequence elucidated 
(102, 103). This large molecular weight prorenin is converted to 
active renin intracellularly. Plasma and other biological fluids 
are also known to contain a form of renin with negligible 
enzymatic activity. The origin of the experimental data 
describing the existence of this 'inactive1 renin can be traced 
to the work of Lueibera in 1971. She showed that amniotic fluid 
dialysed to a pH of 3.3, and then back to 7.4, showed a higher 
renin concentration than amniotic fluid dialysed to pH 4 or 
above. She suggested that this effect was due to the activation 
of an inactive form of renin by acid (104).
Inactive renin may be activated in vitro using a variety of 
procedures. These procedures involve acidification, cold 
treatment or the use of proteolytic enzymes. Acid activation of 
inactive renin has been mentioned above. If proteolytic enzymes 
are added to plasma, amniotic fluid or kidney extracts, and the 
proteolytic activity arrested before the mixture is assayed for 
renin, an increase in renin concentration may occur. Trypsin 
(103), Cathepsin D (106), plasmin (107), glandular kallikrein 
(108) and plasma kallikrein (109) are all effective as activators 
of inactive renin. The exposure of human plasma to a temperature 
of -3°C for 4 days results in an increase in renin enzymatic 
activity (110), but to a lesser extent than treatment with either 
acid or trypsin.
The biochemical nature of inactive renin has been the
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subject of ouch speculation (111, 112) but remains as yet, 
largely unknown. The moat likely explanation ia that inactivs 
renin in a proenzyme precursor of active renin. Thia being so, 
an increase in active plasma renin concentration mould be 
associated with a decrease in inactive plasma renin 
concentration. Although the findinga of a number of studies 
support this claim (113, 114), the evidence ia by no means 
conclusive (115). Alternatively, inactiva renin might be an 
inhibitor-bound form of active renin. The inhibitor could be 
present in the same cell as active renin, or could be aynthesised 
elsewhere, to bind with active renin after active renin has been 
released.
The physiological importance of inactive renin to the 
organism is obscure. The demonstration of an event in a 
test-tube does not mean that the event occurs In vivo; much less 
that it is of biological significance to the organism.
Nevertheless, the reports that both kallikrein (108, 109) and 
plasmin (107) can activate inactive renin suggests that this 
activation may occur in vivo. This being so, the heterogeneity of 
the renin molecule is of significant relevance to thia 
investigation.
Compared to other species, reports concerning an inactive 
form of renin in the rat are few in number and contradictory in 
nature. Moreover, there have been no reports of the effect of 
oestrogen on inactive renin in the rat. A solitary report by 
Hedlin, et al (116) showed that circulating inactive renin levels 
were normal in women ingesting oral contraceptives.
From the preceding chapter, it will be remembered that 
oestrogen treatment had a marked effect on renal haemodynamics.
An increased renin-angiotensin activity (active renin) could not
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satisfactorily account for thia affect. It la tempting to 
apaculata therefore, that convereion of inactive to active renin 
- perhaps mediated intrarenally by lesili kreiiv may be an 
important contributory mechanism to the development and 
maintenance of an increased renal vascular resistance during 
oestrogen treatment.
The objectives of this study therefore, were to clarify the 
uncertainty surrounding the existence of an inactive form of 
renin - of both plasma and renal origin - in the ret, and if 
appropriate, to assess the influence of oestrogen treatment on 
inactive renin. By using specimens obtained from the oestrogen 
treated rets described in the preceding chapter, it may be 
possible to ascertain the pathophysiological significance of the 
heterogenous renin molecule to haemodynamic function, in the 
oestrogen treated rat.
4.2 METHODS
The plasma and renal cortex tissue used for this study were 
obtained from the control and oestrone acetate treated groups A 
(5 mg oestrogen) and B (10 mg oestrogen) described in the 
preceding chapter. The materials and methods used to measure 
both plasma renin activity and renal renin concentration have 
been fully described in chapters 2 and 3. The incorporation of 
trypsin treatment and acidification into Stage 1 (Generation of 
angiotensin I) of these methods, to facilitate the measurement of 
inactive plasma and renal renin respectively, is described below. 
These procedures allow the simultaneous measurement of both 
inactive and active (plasma renin activity and renal renin 
concentration) renin. Data relating to plasma renin activity 
measurements have been previously presented in chapter 3.
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4.2.1 The Effect of Trypsin Treitaent on Pliw  Renin Activity
The presence of a trypsin activable fore of renin in 
rat plasma has been described (117, 118). The following 
procedure, based on these reports, was adopted to 
investigate the effect of trypsin treatment on plasma 
renin activity. Immediately prior to use, trypsin (type 1 
X, Sigma, UK) and soya bean trypsin inhibitor (Type IS, 
Sigma) were dissolved in incubation buffer pH 6.5, to give 
stock solutions of 60 and 66 mg per ml respectively.
After the addition of 5 pi inhibitor cocktail during 
stage 1 (See p 36 )( 25 pi trypsin solution was added to 
the incubate, to give a final concentration of trypsin in 
plasma of 6 mg per ml. The mixture was incubated at 4°C 
for 4 minutes. The action of trypsin was terminated by 
the addition of 25 pi soya bean trypsin inhibitor solution 
(6.6 mg per ml plasma). 50 pi incubation buffer was added 
to control plasmas. The concentrations of trypsin and 
soya bean trypsin inhibitor used in this study have been 
shown to affect maximal activation of inactive plasma 
renin with minimal inhibition and degradation of renin 
(117). Samples were incubated and assayed for renin 
activity as previously described.
The angiotensin I generated from trypsin treated and 
control samples was termed total renin activity (TRA) and 
plasma renin activity (PRA) respectively. Inactive renin 
was defined as the difference between these two 
measurements (TRA - PRA).
4.2.2 The Effect of Acidification on Renal Renin Concentration
The existence of an acio activable from of renin in
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human kidney has been described by Hsueh, et el (119).
The following procedure, based on this report, was used to 
investigate the effect of acidification on renal renin 
concentration.
After homogenisation of the cortex sample and 
subsequent centrifugation of the homogenate, a 1 ml 
portion of homogenate supernatant was placed in dialyaia 
tubing (Scientific Industriea, UK). The supernatant was 
dialysed against approximately 20 volumes of 0.05H glycine 
buffer pH 3.3, for 20 hours, and then redialysed to pH 7.5 
against incubation buffer for a further 20 hours. Another 
1 ml portion of supernatant was dialysed against
incubation buffer pH 7.5 for 40 hours and used as the
odialysed control. Dialysis took place at 4 Ct both acid 
and neutral buffers contained 01M sodium chloride.
Portions of undialysed and dialysed supernatant were 
subsequently assayed for protein content and renin 
concentration respectively. The angiotensin I generated 
from acid dialysed and control samples was termed total 
renal renin concentration and renal renin concentration 
respectively. As for plasma, inactive renin was defined 
as the difference between these two sets of measurements - 
TRC - RRC.
4.3 RESULTS
The injection of vehicle alone did not alter any of the 
parameters under study (Table 4.1). As in chapter 3 therefore, 
data from vehicle injected animals has been pooled and referred 
to as the control group, against which oestrogen treated animals 
have been compared (Table 4.2 and 4.3).
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Effect of Trypsin Treatment on Plaama Renin Activity (Table 4.4
and Fig 4.1)
Trypain treatment resulted in a significant increase in 
plasma renin activity from 8.35 ♦ 1.22 to 8.90 ♦ 1.13 ng ang 1 ml"* 
hfl (p< 0.05) in controls. Whilst trypsin treatment also led to 
an increase in plasma renin activity in both group A, from 6.97 ♦ 
1.39 to 10.91 ♦ 1.39 ng ang I ml"1 h f 1 ( p <  0.001) and group B, 
from 12.67 ±1.59 to 13.6B±1.02 ng ang I ml"1 h r 1 (NS), the 
change in plasma renin activity noted in group B was not 
statistically significant.
Effect of Acidification on Renal Renin Concentration (Table 4.4
and fig 4.2)
Acidification resulted in a significant increase in renal 
renin concentration from 10,632 ♦ 1,082 to 11,606 ♦ 1,268 ng ang 
I mg-1 hr_A (p< 0.001) in controls. Acid dialysis also led to 
significant increases in renal renin concentration in oestrogen 
treated animals. Renal renin concentration rose from 7,025 ♦
1,288 to 7,914 ♦ 1,427 ng ang I mg-1 hrl ( p <  0.01) in group A, 
and from 5,934 ♦ 819 to 6,372 ♦ 833 ng ang I mg-1 hr"l ( p <  0.01) 
in group B.
Effect of Oestrogen on Inactive Renin
Inactive plasma renin concentration (total renin activity - 
plasma renin activity) was 0.72:0 - 2.17 ng ang I ml"l hfl in 
controls, which comprised 9.67 * 3.57 2 of total renin activity.
The administration of 5mg oestrogen caused a significant increase 
in the amount of plasma inactive renin to 3.97 ♦ 1.08 ng ang I mj*! 
hr“l ( p<0.001) or 36.34 ♦ 11.00 2 of total renin activity. No 
significant amount of inactive renin was detected in the plasma 
of rats who received 10 mg oestrogen.
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Inactive renal renin concentration (total renin 
concentration - renal ranin concentration) was 986:0 - 3,488 ng 
ang 1 mg -1  hr-1  or 7.87 ♦ 2.20X of total renin concentration, in 
controla. Oestrogen treatjeent did not altar these values (820:0 
- 2,938 and 300 ♦ 206 ng ang I eg" 1 hr-* , or 12.00 ♦ 4.08 and
8.00 ♦ 3.37 X of total ranin concentration in groups A and B 
respectively).
Relationship Ir>.ctiv. and Active Renin (Fig 4.,)
Using data froe all experieental animals, a significant 
inverse correlation was noted between inactive and active plasma 
renin ( p< 0 .0 0 1). further, the regression of inactive renin on 
active renin was found to be significant (p<0.001)e No such 
relationship was noted between inactive and active renal renin.
4.4 DISCUSSION
The findings from this study have demonstrated the presence 
of a trypsin-activable form of inactive renin in rat plasma. 
Whilst the administration of 5 mg oestrogen resulted in a 
significant increase in this inactive renin, no inactive renin 
was detected in the plasma of rats which received 10 mg 
oestrogen. An acid-activable form of inactive renin was detected 
in rat renal extract. This inactive renin was not affected by 
oestrogen treatment. An inverse relationship was noted between 
inactive and active plasma renin, with changes in inactive renin 
being dependant upon changes in active renin.
The existence of an inactive form of renin in human plasma 
is well established, and accounts for greater than 50X of total 
renin (120). In the rat however, controversy surrounds the 
existence of an inactive form of plasma renin. Osmond and Cooper 
(1 2 1) were unable to detect any inactive renin, using methodology 
which had successfully detected this renin in several other
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specie«. On the other hand, Vandongen, et el (122) detected 
inactive renin in plasma taken fro* anaesthetised animals, which 
accounted for 10% of total renin. Using unanaesthetiaed animals, 
Glorioso, et al (118) and Barrett, et al (117) also detected an 
inactive form of renin which comprised 40 and 85% of total renin 
respectively. The present finding of an inactive fora of plasma 
renin which accounted for 8% of total renin, is concordant with 
the latter reports and closely matches the findings of Vandongen, 
et al.
If controversy surrounds the presence of an inactive form of 
renin in rat plasma, then the existence of an inactive renin of 
renal origin is even more uncertain. Using identical 
acidification procedures, Lauritaen, et al (123) could not detect 
inactive renal renin in the rat, but were able to detect inactive 
renin in porcine renal extracts. Nakane, et al (124) found that 
renin released from isolated perfused rat kidney was not 
activated by acidification. In contrast to these reports, Morris 
and Johnston (125) have reported the presence of an 
acid-activable form of inactive renin in rat renal extract. The 
present finding, that acidification increased the renal renin 
concentration of crude renal extract is in agreement with the 
latter report.
Data from several species including the rat, indicate that 
the kidney contains an inactive form of renin (119, 123, 125-127) 
which is the major source of the inactive material present in 
plasma (115,128). A recent study by Takii, et al (129) provides 
strong evidence to support the concept that inactive renin is a 
proenzyme precursor for renin. The reciprocal relationship which 
was noted between inactive and active renin in the present study 
is in agreement with this concept.
Parallel measurements of inactive renin from peripheral and
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renal venous plasma suggest that activation of circulating 
inactive renin is a physiological event, occurring at an 
intrarenal site (119). The observation that urinary (renal) 
kallikrein is a potent activator of plasma inactive renin 
suggests that intrarenal kallikrein is the physiological 
activator of circulating inactive renin (108). Conversion of 
inactive to active plasma renin might therefore be an important 
physiological event, serving to regulate the amount of 
angiotensin II available to the renal circulation, as a 
suplemental mechanism to the process of renin release.
Oestrogens are known to stimulate the kallikrein-kinin 
system (42,43). They may achieve this either by a direct effect 
or through the renin-angiotensin axis (130, 131). The changes in 
plasma inactive renin noted in this study may reflect an 
influence of oestrogen on kallikrein-mediated conversion of 
inactive to active plasma renin, for example, an increase in 
kallikrein secretion may have enhanced the conversion of inactive 
to active plasma renin (thus depleting plasma inactive renin) in 
rats which received 10 mg oestrogen. The increased intrarenal 
generation of angiotensin II which would ensue, may have 
contributed to the maintenance of the increased renal vascular 
resistance which was noted in these animals.
In conclusion, this study has provided evidence irfiich is 
consistent with the presence of an inactive form of renin in both 
the kidney and plasma of the rat. Evidence was also found to 
support the concept that inactive renin is a proenzyme precursor 
for renin. It has been suggested that oestrogen may influence 
kallikrein-mediated conversion of inactive to active renin. This 
effect might contribute to the maintenance of an increased renal 
vascular resistance in the oestrogen treated rat.
70
Chapter S
THE EFFECTS OF ANGIOTENSIN II BLOCKADE ON RENAL AND SYSTEMIC 
HAEMODYNAMICS IN THE OESTROGEN TREATED NORMOTENSIVE RAT.
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5.1 INTRODUCTION
The findings fro« Chapters J and 1» clearly show that 
oestrogen-induced changes in both renal and systeeic 
haemodynamics in the rat were associated with marked alterations 
in the renin-angiotensin system. Whilst these findings suggest 
that this system is involved in implementing the haemodynamic 
changes, they provide no supportative evidence, and permit no 
precise conclusions as to the nature of the involvement.
The classical method of discovering the function of an 
endocrine system in various physiological and pathological states 
is to eliminate the source of the hormone. This approach is not 
feasible for studies involving the renin-angiotensin system. The 
juxtaglomerular apparatus is in intimate contact with the organ 
it exerts a major influence upon, the kidney. However, the 
recent advent of pharmacological compounds, which can interrupt 
the renin-angiotensin system at critical stages between renin 
secretion and the interaction of angiotensin II with its 
receptors, now allow temporary, reversible ablation of the 
renin-angiotensin system. The two most widely used classes of 
inhibitors of the renin-angiotensin system are angiotensin 
converting enzyme inhibitors and angiotensin II analogues. These 
pharmacological tools have been invaluable in defining the role 
of the renin-angiotensin system in both normal (146-148, 155) and 
abnormal (149,150,156) cardiovascular function. Their 
application, to discover the importance of angiotensin II to the 
maintenance of arterial pressure and renal blood flow in the 
salt-deplete state, has been mentioned during the course of this 
investigation.
Converting enzyme inhibitors, such as captopril, block the 
cleavage of angiotensin I, and thereby prevent the formation of
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angiotensin II (151). These compounds also inhibit the 
degredstion of kinins however, potentiating the vasodilatory 
property of these substances (152). Caution is therefore 
necessary when interpreting haemodynamic changes sssocisted with 
the use of a converting enzyme inhibitor.
A number of angiotensin II analogues have been synthesised 
by making amino acid substitutions at each position in the 
sequence of the netive hormone (153). The combined substitution 
of sarcosine in position 1 - which confers long life and 
increased binding affinity, and alanine in position 8 - which 
confers antagonistic properties, has resulted in the synthesis of 
Sar 1, Ala 8 - angiotensin II, or Saralasin - the most commonly 
used analogue of angiotensin II.
Saralssin competes with angiotensin II for avsilable 
receptor sites, and is a competitive antagonist. Like all of the 
peptide antagonists of angiotensin II synthesised to date, 
saralasin may also act as a partial agonist. This intrinsic 
activity can be found in tissues which are most sensitive to 
angiotensin II, such as the renal vasculature (154).
Angiotensin II analogues have been useful in clarifying the 
role of angiotensin II in both normal cardiovascular homeostasis 
(146-148) and abnormal cardiovascular function (149-150), in 
characterising angiotensin II receptors (154,157) and in 
providing a potential for the elucidation of the aetiology or 
human hypertension under some circumstances (149,158). Of 
particular interest to this study are the reports that saralasin 
affected a fall in arterial pressure, both in pregnant rats 
(159), and in rats receiving an oestrogen-containing oral 
contraceptive (160). These reports support the contention that 
an increased concentration of circulating angiotensin II is a 
causal factor in mediating
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oestrogen-induced haemodynamic disturbances.
The objective of this study therefore, mss to sssess the 
contribution Af angiotensin II to haemodynamic function in the 
oestrogen treated rat, through the use of the angiotensin II 
analogue, saralaain.
5 . 2  m m
Oestrone acetate in ethyl oleate (4 mg per ml) was used to 
give subcutaneous injections of 1 mg oestrogen per day for 10 
days, to a group of adult female Sprague-Damley rata (170 - 240 
g). Animals were housed and fed as described in chapter 3. 
Control animals received a daily injection of vehicle for 10 
days.
24-hours after their last injection of either vehicle or 
oestrogen, animals were prepared for experimental analysis as 
described in chapter 2 . in addition, a third polythene catheter 
(outer diameter = 0.75 mm) was secured in the left femoral vein 
of oestrogen treated rats, to facilitate intravenous infusion.
In control animals, renal and systemic haemodynamics, plasma 
and renal renin and the packed cell volume were measured as 
described in chapter 2. In oestrogen treated animals, resting 
mean arterial pressure was measured using the carotid catheter. 
Animals were then infused with either saline (0.034 ml per min) 
or saralasin (Sarenin, 2 pg per min: Rohm, W. Germany) diluted in 
saline, for 15 minutes, using a Braun (W. Germany) 871104 
continuous drive perfusor. This amount of saralasin was found to 
inhibit the pressor response to a lOng bolus of angiotensin II 
injected intravenously into oestrogen treated rats (160 ). At the 
end of the infusion period mean arterial pressure was again 
measured. The carotid catheter was advanced into the left 
ventricle, and cardiac output, renal blood flow and
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vascular resistance determined as described in Chapter 2 . Plasma 
and renal renin and the packed cell volume were also measured as 
described in this chapter.
Statistics
The effect of infusions, on both mean arterial pressure and 
haart rata, have been analysed by comparing those values obtained 
prior to infusion to those values noted immediately after the 
infusion of aither saline or saralaain. Data were analysed using 
a paired t-test. For the remaining parameters, the influence of 
saralasin was assessed by comparing data obtained from animals 
infused with saline to those obtained from animals infused with 
saralaain - using a one way analysis of variance.
5.3 RESULTS
As in preceding chapters, the injection of vehicle did not 
«ffect any of the parameters under study (Table 5 .1). Data from 
these animals was therefore combined for the purpose of 
comparison with oestrogen treated animals.
The Effects of Saralasin on Haemodynamics and the 
Renin-Angiotensin Systeai (Table 5.2 and Figures 5.1 and 5.2)
Mean Arterial Pressure and Heart Rate
Prior to the infusion of saline, mean arterial pressure and 
heart rate were 126 + 8 mm Hg and 355 ♦ 22 beats per min (n » 9). 
at the end of the infusion period these values remained unchanged 
at 126 ♦ 9.5 mm Hg and 365 ♦ 13 beats per min.
The infusion of saralasin had no significant effect on 
either mean arterial pressure (136 ♦ 6 v. 120 ♦ 8 mm Hg) or heart 
rate (384 ♦ 24 v. 390 ♦ 14 beats per min. n = 10).
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Total Peripheral Resistance and Cardiac Output
Saralaaln infusion resulted in an increase in total 
peripheral resistance from 32,301 ♦ 4,322 to 48, 779 ♦ 12,934 dyn 
cm * sec“* kg-* (p<0.05), and a decrease in cardiac output from 
321 ♦ 33 to 240 ♦ 53 ml mirt" 1 kef1 (p<0.05).
Renal Haemodynamics
Although saralasin reduced renal blood flow from 5.31 ♦ 0.82 
to 3.41 ♦ 1.49 ml mirT* g** , this change did not achieve 
statistical significance (p< 0.1 >0.05). An increase in renal 
vascular resistance from 2,054 ♦ 502 to 4,504 ♦ 1,750 dyn cir5 
8ec_* (p<0.05) was noted after saralsin infusion.
The Renin-Angiotensin System
An increase in both plasma renin activity from 11.79 ♦ 3.31 
to 79.83 ♦_ 28.04 ng Ang I ml hr (p<0.001), and plasma renin 
concentration fro. 21.3 .4.5 to l»7.i . 02.» ng Ang I .l* 1 hr' 1 
( p< 0 .0 0 1), was noted after saralasin infusion.
Renal renin concentation fell from 6,237 ♦ 998 to 3,076 ♦
688 ng Ang I mg * hr”* (p<0.001) after saralasin infusion.
Packed Cell Volume
Saralasin increased the packed cell volume from 29.9 ♦ 1.6 
to 33.8 ♦ 2.2 % ( p< 0.05). Thia latter value was significantly 
smaller than the value recorded for non-oestrogen treated rats (F 
s 10.98, p <  0.01).
5.4 DISCUSSION
The findings from this study have shown that in the 
oestrogen treated rat, an intravenous infusion of saralasin 
resulted in a 119S increase in renal vascular resistance, and a 
51S increase in peripheral vascular resistance. Both plasma 
renin activity and concentration increased markedly after
TABLE 5 .1 . Effect of Vehicle (ethyl oleate) Injection on Haemodynamics.
THb Renin-Angiotensin Syatam end Pecked Cell Uni,—
Dete ere presented es either e mean ♦ 95* C.L., or a median end 
range. In the test column an F value indicates the use of a 
one way ANOVA, and a Z value the use of the Uilcocon Rank Sum test. NS s not significant
PARAMETER NON TREATED VEHICLE - 0 
per day for
25 al 
10 daya !£S1
Mean Arterial 
Pressure mm Hg
1171A ns9 124:
114-140
nslO Zs-1.10 NS
Heart Rate 
beats per min - 397120 ns5 ) M ±10 n* 10 Fs 0.86 NS
Cardiac Output 
ml min -1  kg-1 240125 ns9 236227 nslO Fs 0.06 NS
Stroke Volume 
ml beat kg~l 0.573).04 n«5 0.6120.08 nslO Fs 0.49 NS
Total Peripheral
Resistance
dyn cm-5 sec-1 kg-1
39,89014,416 n=9 42,41914,777 nslO Fs 0.57 NS
Renal Blood Floe 
ml min~l g-l 5.3520.82 ns9 5.9720.65 nslO Fs 1.37 NS
Renal Vascular
Resistance
dyn cm-5 sec-1  kg-1
1,743
1,315-3,154 n*9 1,6671176 nslO Zs 0.24 NS
Plasma Renin 
Activity
ng Ang I ml“l hr-1
7.8810.69 ns5 8.9012.06 ns9 Fs 0.48 NS
Plasma Renin 
Concentration 
ng Ang I ml“l hr“*
97.90126.07 n«5 109.6132.3 ns9 Fs 0.23 NS
Renal Renin 
Concentration 
ng Ang I m«-l hr-1
11,19212,435 n=4 9,59011,011 nslO Fs 0.04 NS
Packed Cell * 
Volume 
*
37.911.6 n*5 37.511.6 nslO Fs 0.09 NS
JiStLiil- LIfKt of S.r.U.in Infu.ion U »  - 2 nq M r  .In for 15 .In) on 
».«■odyn— ic, th. ltohin-Anqiot.n«in Sy.t». .rxi th. P.ci..d C.il 
y9lu.. in H.t. Ciwen 1 mg O..tron. t o f t ,  per d.v for 10 a.».. 
Legend as described in Table 5.1. Values for mean arterial 
pressure end heart rste are given for both before (B) and after (A) infusion.
PARAMETER » i * SARALASIN TEST
Mean Artarial B 
Pressure A mm Hg
1262«
126*9.S n= *
13616
12818 n*1Q "
Heart Rate B 
beats per min A 355122365113 n“ 9 384124390114 n *10 -
Cardiac Output 
ml min"* leg"* 321133 n> 8 240153 nslO Fa 5.82 •
Stroke Volume 
ml beat"* kg"* 0.9310.10 ns 8 0.6310.14 nslO Fs 9.45 *
Total Peripheral
Resistance
dyn cm" 5 sec"*kg"*
32,30116,322 ns 6 48,779112,934 nslO Fs 4.61 *
Renal Blood FIom 
ml min"* g"* 5.3110.82 ns 8 3.4111.49 nslO Fs 4.13 NS
Renal Vascular
Resistance
dyn cm" 5 sec"* kg"*
2,0541502 ns 8 4,50411,750 nslO Fs 5.66 *
Plasma Renin 
Activity
ng Ang I ml"* hr"*
11.7913.31 n=10 79.83128.04 nslO Fs21.95 ***
Plasma Renin 
Concentration 
ng Ang I ml"* hr"*
21.314.5 nslO 197.6182.9 nslO Fsl7.31 ***
Renal Renin 
Concentration 
ng Ang I mg"* hr"*
6,2271998 n=10 3,0761688 nslO F = 26.09 ***
Packed Cell Volume 
X 29.911.6 nslO 33.812.2 ns 9 Fs 7.23 •
65,000
55.000
Total
Peripheral
Resistance
45.000
(dyn ce-5sec-1k*-l)
35,000
5.000
Renal
Vascular
Resistance
4.000
(dyn c«“®sec_1kg“^)
3.000
{
SALINE SARALASIN
VEHICLE
CONTROLS
F igure 5.1 The Effects of Scralaain (i.v. -2pg per win, for 15 win.)
on Total Peripheral Resistance and Renal Vascular Resistance 
in Oestrogen Treated Rats. Both groups of animals received 
lmg of oestrone acetate per day for 10 days.
100
Renin
Activity
(ng anglml-1hr_1)
Plasma
Renin
Concentration 
(ng anglml-1hr"
200
•M
100
i
SALINE SARALASIN
VEHICLE
CONTROLS
Figure $ .2 The Effects of Saralasin (i.v. —2yg per min, for 15min. )
on the Plasma Renin Activity and Concentration of Oestrogen
Treated Rats. Both groups of animals received lmg of oestrone 
acetate per day for 10 days.
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saralasin infusion.
In the normal, anaesthetized rat, saralasin acts as an 
antagonist, but has no effect on blood pressure, cardiac output, 
vascular resistance or renal blood flow (148,161). Data from the 
present study indicates that saralasin exhibits agonistic-like 
activity in the oestrogen treated rat, as evidenced by an 
increase in vascular resistance after infusion of the agent.
This activity ia a consequence of the structural aiailaritiea 
between saralasin and angiotensin II. Thus, whilst the analogue 
has affinity for angiotensin II receptors, it also exhibits 
intrinsic activity - albeit to a far lesser extent than the 
primary agonist. The agonistic property of saralasin is not 
apparent under normal circumstances (148,161), but may become 
pronounced in states characterised by sodium overload. Thus, in 
both metacorticoid- and deoxycorticosterone acetate 
(DOCA)-induced hypertension, saralasin not only failed to lower 
blood pressure, but elicited a pressor response (150,162). 
Likewise, in the salt-loaded rabbit, saralasin was found to 
induce a fall in renal blood flow (154). Throughout this 
investigation a reduction in the packed cell volume (that is, an 
increase in plasma volume) has been a hall-mark of oestrogen 
treatment. The findings of the present study thus agree with the 
reports which have shown that the agonistic activity of saralasin 
becomes prominent in states characterised by sodium overload.
Numerous studies have shown that 
variation in dietary sodium intake alters the concentration of 
circulating angiotensin II (135,136). Bellucci and Wilkes have 
shown that this manoeuvre also modulates the density of vascular 
angiotensin II receptors ( 153 ). A reduced concentration of
circulating angiotensin II (consequent to sodium surfeit)
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resulted in up-reguletion of sngiotensin I I  recepton, and 
vice-versa. By dissociating the effect of d i etary sodium from that 
of circulating-sngiotensin I I  (by infusing sngiotensin I I  into 
the circulation), these authors were able to show that 
angiotensin I I  itself directly influences receptor equilibrium.
The pronounced intrinsic activity of saralasin, in the oestrogen 
treated rats described in this study, may therefore be the result 
of an increase in the density of vascular angiotensin I I  
receptors in these sodium loaded animals.
The stimulatory effect of oestrogen on angiotensin I I  
receptor number in both the myometrium (47) and the glomeruli of 
normotensive rats (A.MSssenger:pers.ccmmj has been discussed 
previously. These observations suggest that oestrogen may 
increase the density of vascular angiotensin I I  receptors 
independently of circulating angiotensin I I .  Moreover, this 
effect of oestrogen would appear to have a major expression on 
renal vasculature, where it may, in the presence of an increased 
concentration of angiotensin I I ,  lead to an increase in renal 
vascular resistance.
The blood pressure of oestrogen treated rats was not 
affected by the infusion of saralasin, and remained significantly 
elevated compared to control animals. This observation ia in 
contrast to the finding of Stubbs, et al (160), where the same 
amount of saralasin was found to return the blood pressure of 
rats with oral contraceptive-induced hypertension to pretreatment 
levels. Although peripheral vascular resistance was not measured 
in this report, the fall in blood pressure was presumably due to 
a decrease in this variable - the result of an antagonistic mode 
of action by saralasin. This is in contrast to the present 
study, where an agonistic mode of action by saralasin resulted in 
an increase in vascular resistance. An actual increase
7*
in arterial preaaure with aaralaain wight therefore have occurred 
in these animals, had not cardiovaacular reflexes initiated a 
compensatory fall in cardiac output.
The report of Stubbs, at al and the present study, indicate 
that the renin-angiotensin system way wediate oestrogen-induced 
disturbances in cardiovascular function by wore than one pathway.
The difference in findings between these two studies nay well be 
due to differences in the nature of the oestrogen preparation 
used. Stubbs, et al used the synthetic oestrogen - enovid, 
whereas the natural oestrogen - oestrone has been used in the 
present study. Moreover, the studies which have reported 
increases in angiotensin II receptor number with oestrogen 
treatment (47, a .Messenger:pers.comm. )also used natural 
oestrogens.
Under normal circumstances, angiotensin II exerts an 
inhibitory effect on renin secretion, through a direct negative 
feedback mechanism. This effect is believed to be mediated by a 
vascular receptor in the afferent renal arteriole, or by a direct 
effect on the juxtaglomerular cells. In the normal, 
anaesthetised rat, saralasin causes an increase in renin 
secretion (164). This effect has been interpret«ted to represent 
blockade of the negative feedback pathway described above. In 
the presence of an increase in renin substrate synthesis, this 
effect of saralasin would explain the dramatic increases in both 
plasma renin activity and concentration noted in oestrogen 
treated rats after saralasin infusion.
In conclusion, saralasin has been found to exhibit intrinsic 
activity in the oestrogen treated rat, which has a marked 
expression on the renal vasculature. This effect did not permit 
any conclusions as to the contribution of angiotensin II
7Q
to haemodynamic function in tha oestrogen treated rat. It haa 
been suggested that the intrinsic activity of saralasin was the 
result of an oestrogen-induced increase in vascular angiotensin 
II receptor number. This effect of oestrogen may contributs to 
an increase in renal vascular resistance in the oestrogen treated 
rat.
*0
Chapter 6
A COMPARISON OF THE CIRCULATORY AND HORMONAL RESPONSES TO OESTROGEN 
TREATMENT BETWEEN THE SPONTANEOUSLY HYPERTENSIVE
RAT AND ITS NORMOTENSIVE COUNTERPART
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6-1 INTRODUCTION
Disturbances in haemodynamic homeostasis - manifested as 
hypertension - are a recognised complication in women ingesting 
oestrogen-containing oral contraceptives (JJ, 54, 165, 166). 
These compounds have also been shown to exacerbate pre-existing 
hypertension (165, 166). As a consequence of this latter 
observation, ethical considerations have precluded detailed 
studies of the effect of oestrogen on cardiovascular function in 
hypertensive humans.
Adequate animal models for human diseases form important 
elements in the experimental study of their pathogenesis. Animal 
■»dels for human diseases that are caused exogenously, such as 
infectious diseases and nutritional deficiency, have been 
relatively easy to establish. Hereditary hypertension, on the 
other hand, is multifactorial in nature, reflecting an 
interaction between genes and the environment. Thus, development 
of a satisfactory animal model of human hypertension represents a 
particularly difficult undertaking. The development of strains 
of hypertensive rats in the late 1950'a and early 1960's (167, 
168) heralded an important breakthrough in hypertension research. 
These strains have gradually replaced experimentally induced 
hypertensive animal models such as renal and deoxycorticosterone 
acetate (DOCA) hypertension, which had been preponderantly used 
for hypertension research.
Reports of the effects of oestrogen on cardiovascular 
function in animal models of hypertension are few in number, and 
inconsistent in their findings. Where hypertension has been 
experimentally induced, oestrogens have been reported either to 
exacerbate (169), or to have no effect (170) on the
hypertension. Similarly, in genetically hypertensive rets, 
oestrogen has been shown either to enhance hypertension when 
given alone (171) or in conjunction with a high salt diet (170), 
or to have no effect on blood pressure (170). These animal 
studies, being confined to blood pressure measurements alone, do 
not provide a complete haemodynamic picture - preventing 
conclusions as to the underlying mechanisms responsible for the 
blood pressure changes.
The objectives of the present study were two-fold, firstly, 
to compare the influence of oestrogen on haemodynamic function 
and plasma and renal renin in the spontaneously hypertensive rat 
(SHR) and their normotensive Wister Kyoto (WKY) counterparts, arri 
secondly, to investigate specifically the role of angiotensin II 
in any observed changes - by the use of the angiotensin 
converting enzyme inhibitor, captopril.
6 .2  TCTHOOS
Adult female spontaneously hypertensive rats (SHR: 190 - 235 
g) and their normotensive Wistar Kyoto counterparts (WKY: 180 - 
245 g) were used throughout the study (Olac Ltd, England).
Animals were housed and fed as described in Chapter 3.
Oestrone acetate in ethyl oleate (4mg per ml) was used to 
give subcutaneous injections of 1 mg oestrogen per day for 10 
days, to both SHR and WKY rats. Control animals received an 
injection of vehicle alone.
24-hours after receiving their last injection of vehicle, 
vehicle-injected rats were prepared for experimental analysis. 
After receiving their last injection of oestrogen, oestrogen 
treated rats were split into two batches. The first batch of
animals mas prepared for experimental analysis aa for vehicle- 
injected animals. The second batch of rats were fasted 
overnight, prior to receiving a single dose (P.0.) of either 
Captopril (30 mg per kg) or 0.9* saline vehicle (1 ml) by gavage. 
Rats were then prepared for experimental analysis. The dose of 
captopril used here has been shown to inhibit the pressor 
response to 100 ng per kg of angiotensin II (i.v.) within 10 
minutes, an effect which lasts for 2-3 hours (172).
Haemodynamic and renin-angiotensin variables and the packed 
cell volume of blood were measured as described in chapter 2 . 
for the second batch of rats, haemodynamic measurements were made 
approximately 90 minutes after administration of captopril or 
saline.
6.3 RESULTS
The injection of vehicle alone did not alter any of the 
parameters under study in both SHR and WKY rats (except for the 
packed cell volume (Table 6.1)). for statistical purposes 
therefore, data from unmanipulated rats has been combined with 
data from the corresponding strain of vehicle-injected rats. The 
two groups of animals thus formed are referred to as non­
oestrogen treated controls.
Comparison of the Data Obtained From the Non Oestrogen Treated 
Control Croups of WKV and SHW (Table 6.2)
Mean arterial pressure and peripheral and renal vascular 
resistance were significantly greater in the SHR compared to WKY 
rats. There was no difference in cardiac output, stroke volume, 
renal blood flow and packed cell volume between the two strains 
of rats.
Renal renin concentration was significantly lower in the 
SHR. There was no other significant differences in the remaining 
parameters of the renin-angiotensin system under study.
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The above observations are in agreement with published data
(173).
The Effects of Oestrogen in IKY (Tableó.3)
Haemodynamics
Mean arterial pressure rose from a control value of 120 ♦ 6 
to 140 ♦ B mm Hg (p< 0.001) after oestrogen treatment. Cardiac 
output and atroke volume increaaed from 300 ♦ 46 and 0.77 ♦ 0.10 
to 369 ♦ 39 ml kg-1  min" 1 (p< 0.05) and 0.95 ♦ 0.10 ml beat" 1 kg" 1 
(p< 0.05) reapectively. Oestrogen treatment had no effect on 
total peripheral resiatance (33,660 ♦ 5,141 v 31,051 ♦ 3,332 dyn 
cm- 5  eec" 1 kg"1).
A fall in renal blood flow - from 7.71 ♦ 1.00 to 6.25 ♦ 0.57 
ml g" min " 1 ( p< 0.05) - and a rise in renal vascular resistance
- from 1,282 ♦ 131 to 1,830 ♦ 204 dyn cm-'> sec-1  kg-1( p <  0.001)
- took place as a result of oestrogen treatment.
Renin-Angiotensin System
Plasma renin activity increased from a control value of 2.29
♦ 0.43 to 4.73 ♦ 2.10 ng Ang I ml " 1 hr-1(p< 0.05) after 
oestrogen treatment. Whilst oestrogen treatment had no effect on 
plasma renin concentration (9.13 ♦ 2.12 v 8.39 ♦ 2.9 ng Ang I m f 1 
hr " 1 ), renal renin concentration fell from 6,248 ♦ 800 to 4,616
♦ 907 ng Ang I mg -1  hr " 1 (p< 0.05) with oestrogen.
Packed Cell Volume
Oestrogen treatment reduced the packed cell volume from a 
control value of 32.2 ♦ 0.6 to 27.4 ♦ 1.1* (p<0.001)
The Effects of Oestrogen in SHR (Table Ó4)
Haemodynamics (Figure 6.1)
The administration of oestrogen resulted in a fall in mean 
arterial pressure, from a control value of 175 ♦ 5 to 164 ♦
*5
6 mm Hg ( p ^  0.0$). Cardiac output and stroke volume increased 
from 248 ♦ $1 and 0.67 ♦ 0.13 to 369 ±90 ml min-1 kg-1 (p< 0.0$) 
and 1.21 ♦ 0.33 ml beat-1 kg-1 (p< 0.01) respectively. Total 
peripheral resistance decreased from 67,611 ♦ 16,168 to 41,6$0 ♦ 
10,836 dyn cm-5 sec-1 kg-1 ( p <  0.0$) after oestrogen.
A fall in renal blood floe - from 7.23 ♦ 1.12 to $.22 ♦ 0.$$ 
ml min-1 g-1 ( p <  0.0$) - and a riae in renal vascular resistance 
- from 2,078 ♦ 270 to 2,$84 ♦ 294 dyn cm-$ sec-1 kg-l(p< 0.0$) - 
occurred as a result of oestrogen treetment.
Renin-Angiotensin System (Figureó .2)
Oestrogen trestment increased plssma renin activity from a 
control value of 3.34 ♦ 1.02 to 6.20 ♦ 1.39 ng Ang I ml-1 hr-1 (p< 
0.01). Both plasma and renal renin concentration were reduced 
after oestrogen treatment, from 10.21 ♦ 3.29 to 7.47 ♦ 1.78 ng 
Ang I ml-1 hr-1 and 3,182 ♦ 329 to 2,941 ♦ 261 ng Ang I mg-1 hr-1 
respectively. These reductions did not, however, achieve 
atatiatical significance.
Packed Cell Volume (Figureó .2)
A fall in the packed cell volume from 29.9 ♦ 0.$ to 26.9 ♦
1.15 ( p <  0.001) took place as a result of oestrogen treatment.
The haemodynamic, renin-angiotensin and packed cell volume 
responses of WKY and SHR to oestrogen are summarised in Table 6.$ 
The Effects of Captopril on Haemodynamics and the Packed Cell 
Voluee of Oestrogen Treated WKY. (Tableó .6 and Figure 6.3)
Systemic Haemodynamics
Captopril reduced the mean arterial pressure of oestrogen 
treated WKY from a median value of 131, with a range of 130-167 
(saline vehicle controls), to 131 ♦ 9 mm Hg ( p <  0.01). This 
latter value was greater than the 120 ±  6 mm Hg value noted
for non-oestrogen treated control WKY (F • 4.87, p <  0.05).
Although captopril decreased total peripheral resistance 
fro« 41,574 ♦ 8,561 to 51,151 ♦ 6,955 dyn cm-5 sec"1 kg-1, this 
change did not achieve statistical significance. Cardiac output 
was not affected by the adainistration of captopril (515 ♦ 59 v. 
599 ♦ 169 ml «in-1 kg-1).
Renal Haemodynamics
Captopril caused an increase in renal blood flow and a 
decrease in renal vascular resistance, from 5.98 ♦ 0.94 and 2,157 
♦ 576 to 8.24 ♦ 0.80 ml min”1 g " 1 ( p< 0.01) and 1,299 ♦ 149 dyn 
cm *5sec *Akg *A(p< 0.001) respectively. These letter values 
were similsr to those noted in control (non-oestrogen treated) 
animal a (7.71 ♦ 1.00 mi min-1 g-1 and 1,282 ♦ 151 dyn cm'5 sec*1 
kg-1).
Packed Cell Volume
The packed cell volume remained unchanged after 
administration of captopril (28.9 ♦ 1.6 v. 28.8 ♦ 1.4*).
The Effects of Captopril on Hacswdvnamics and the Packed Cell 
Volume of Oestrogen Treated SHR (Table 6.7 and Figure 6.4) 
Systemic Haemodynamics
Captopril had no effect on arterial pressure (154 ♦ 14 v.
141 ♦ 22 mm Hg), cardiac output (565 ♦ 100 v. 519 ♦ 51 ml min-1 
kg*1) or total peripheral resistance (55,840 ♦ 7,597 v. 56,270 ♦ 
5,459 dyn cm “5sec_1 kg-1).
Renal Haemodynamics
The administration of captopril resulted in an increase in 
renal blood flow - from 6.24 ♦ 0.86 to 10.65 ♦ 0.61 ml min*1 g*1 
( p <  0.001) - and a decrease in renal vascular resistance - from 
2,050 ♦ 455 to 1,084 ♦ 165 dyn cm“* sec-1 kg*1 ( p <  0.001).
Thus captopril caused a rise in renal blood flow in
6 7
oestrogen treated SHR to a level above that noted in non- 
oestrogen treated SHR (F* 11.69, p <  0.01), and a fall in renal 
vascular resistance to a level below that of non-oestrogen 
treated SHR (Fs 17.IS, p <  0.001).
Packed Cell volusie
The packed cell volume was not affected by captopril (27.6 ♦ 
1.0 v. 28.0 ♦ 0 .6%).
6.4 DISCUSSION
The findings from this study have demonstrated that whereas 
oestrogen caused a rise in arterial pressure in WKY, it induced 
a fall in pressure in the SHR. A reduction in renal blood flow 
and an increase in renal vascular resistance were noted in both 
WKY and SHR after oestrogen. These haemodynamic changes were 
accompanied by a reduction in the packed cell volume and an 
increase in plasma renin activity, in both straina of rats. 
Administration of captopril resulted in a fall in mean arterial 
pressure in the oestrogen treated WKY, but was without effect in 
the SHR. In the oestrogen treated WKY, captopril returned renal 
blood flow to the pretreatment level. Captopril also increased 
renal blood flow in the oestrogen treated SHR, but to a level 
which was still significantly greater than that observed in non­
oestrogen treated SHR.
The haemodynamic, packed cell volume and plasma renin 
activity and renal renin concentration responses of WKY to 
oestrogen match the responses of the Sprague-Dawley rats (given 
the same amount of oestrogen) described in chapter 3. Although a 
reduction in plasma renin concentration was also noted in WKY 
after oestrogen, this change was not statistically significant. 
This finding does not agree witn the marked reduction in plasma 
renin concentration noted in the Sprague-Dawley animals referred
TABLE: 6.1. Effect» of Vehicle (ethyl oleate) Injection on Haemodynamics.
the Renin-Angiotensin System »nd the Pecked Cell Volume, in 
The Spontaneously Hypertensive Rat.
Data are presented as a mean ♦ 95% C.L. Data were analysed 
using a one way ANOVA. The probability value of the teat 
statistic - f ia indicated in the teat column.
PARAMETER NON TREATED VEHICLE - 0 25 ml IE31per day for 10 days
Mean Arterial 
Pressure mm Hg
18Qt6 ns6 17215 nslO Fs3.83 NS
Heart Rate 
Beats per min
371129 n=6 367115 n=10 FsO.08 NS
Cardiac Output 
ml min"l kgr*
291157 n=6 219172 n* 9 Fsl.94 NS
Stroke Volume 
ml beat-1 kg-l
0.7810.13 n=6 0.6Q10.2 ns 9 Fsl.80 NS
Total Peripheral
Resistance
dyn cur* sec“lkg-l
52,620112,142 n=6 77,605124,106 n= 9 Fs2.43 NS
Renal Blood Flow 
ml mirT* g"l
6.8410.82 n=6 7.5211.90 ns 8 FsO.32 NS
Renal Vascular
Resistance
dyn car5 sec-! kg-!
2,1411216 n=6 2.03H459 ns 8 FsO.14 NS
Plasma Renin 
Activity
ng Ang I ml-lhr-!
2.3H0.67 n=6 4.0»1.51 ns 9 Fs3.00 NS
Plasma Renin 
Concentration 
ng Ang I ml-* hr*l
7.2912.34 n=6 12.1514.98 ns9 Fs2.17 NS
Renal Renin 
Concentration 
ng Ang I mg-! hr*
2,8021186 n=6 3,41(>465 n= 9 F=3.64 NS
Packed Cell 
Volume %
33.410.7 n=6 29.»0.5 ns9 F=61.16 •••
T*BLe6 .2. Haemodynam Ac, Renin-Angiotensin and Packed Cell Volume 
D«t« From Non Oestrogen If«ted Nomotenaive Ulster 
mnd Spontaneously Hypertensive Rats.
Legend ae described in Table 6.1
PARAMETER NORMOTENSIVE SPONTANEOUSLY I£il(n a 10) HYPERTENSIVE 
(n * 15)
Mean Arterial 
Pressure mm Hg 12016 17515 r a 218 **•
Heart Rate 
beats per min
587115 368114 r a 3.05 NS
Cardiac Output 
■1 min“1 kg*‘
300+46 248151 F a 1.98 NS
Stroke Volume 
ml beat* kg"1
0.7710.10 0.6710.13 F a 1.08 NS
Total Peripheral 
Resistance
dyn cm_*eec"1fcg"1
33,660+5,141 67,611116,168 F a 10.67 **
Renal Blood Flow 
ml min"1 g"1
7.7111.00 7.2311.12 F a 0.36 NS
Renal Vascular 
Resistance
dyn cm-5hec"1kg"1
1,2821131 2,0781270 F a 21.0
Plasma Renin 
Activity
ng Ang I ml'1 hr1
2.29+0.43 3.3411.02 F a 1.37 NS
Plasma Renin 
Concentration 
ng Ang I ml-1 hr1
9.1312.12 10.2H3.29 F a 0.29 NS
Renal Renin 
Concentration 
ng Ang I mg-1hr"1
6,2481800 3.1821329 F = 68.48 •••
Packed Cell 
Volume 5
32.210.63 31.311.1 F a 1.69 NS
TABLE 6.3. The Effect» of 10mq Destrone Acetate on Haeamdynaaica. the 
Benin-Anqiotenein Syatea end Pecked Cell Volume in 
Noraotensive Wiatar Bate. Legend as described in Table 6.1
PARAMETER CONTROL 
(n > 10)
OESTROGEN 
?«LATMEfiJ 
(n a 10)
TEST
Mean Arterial 
Pressure mm Hg
120Í6 14018 F a 16.22 *•*
Heart Rate 
beats per ain
387115 389120 F a 0.04 NS
Cardiac Output 
al ain*1 kg-1
300146 369139 F > 5.00 *
Stroke Voluae 
al beat'1 kg-1
0.7710.10 0.9510.10 F * 5.70 •
Total Peripheral
Resistance
dyn ca“* sec-1 kg”1
33,66015,141 31,05113,332 F s 0.07 NS
Renal Blood Flo* 
al g-1 ain-1
7.71Ü.OO 6.2510.57 F a 6.28 •
Renal Vascular
Resistance
dyn ca“* sec^kg-1
1,282H31 1,8301204 F a 19.72 ***
Plasma Renin 
Activity
ng Ang I al“1 hr-1
2.2910.43 4.7312.10 F a 5.54 •
Plasma Renin 
Concentration 
ng Ang I al“1 hr“1
9.1312.12 8.3912.90 F a  0.17 NS
Renal Renin 
Concentration 
ng Ang I eg-1h r"1
6,2481800 *,616±S07 F a 7.00 *
Packed Cell 
Volume S
32.210.6 27.411.1 F a 55.68 ***
TABLE 6.4. The Effects of 10 mg Peatrone Acetate on Haemodynmiiica. the 
Renin-Angiotensin System end Pecked Cell Volume. in the 
Spontaneous!y Hypertensive Ret.
Legend as described in Table 6.1 ♦ -  Oats represents vehicle 
injected animals alone.
PARAMETER CONTROL OESTROGEN 
TREATED 
n s 10
I£SI
Mean Arterial 
Pressure mm Hg
17515 n=16 16416 Fs 7.69 *
Heart Rate 
beats per min
368114 n=16 311118 Fs24.92 —
Cardiac Output 
ml min-1 kg-1
248151 n*15 369190 Fs 6.02 •
Stroke Volume 
ml beat-1 |<g-l
0.6710.13 nel5 1.2110.33 Fall.04 **
Total Peripheral
Resistance
dyn cm~5 sec-1 kg-1
67,611116,168 n=15 41,650110,856 Fs 5.45 •
Renal Blood Flow 
ml min~l g_1
7.2311.12 ns 14 5.2210.55 Fs 7.67 *
Renal Vascular
Resistance
dyn cm-5 sec“1 kg-1
2,0781270 nr14 2,5841294 Fs5.97 *
Plasma Renin 
Activity _x 
ng Ang I ml hr“1
3.3411.02 nsl5 6.2011.39 Fsl0.99 **
Plasma Renin 
Concentration 
ng Ang I ml-1 hr-1
10.2113.29 nsl5 7.4711.78 Fs 1.54 NS
Renal Renin 
Concentration 
ng Ang I mg-1 hr-1
3,1821329 n=16 2,9411261 Fs 1.03 NS
Packed Cell 
Volume \
♦
29.910.5 n= 9 26.911.1 Fs22.9 ***
TABLE 6.3. The Effects of Oestrooe Acetate on Haemodynamics. the 
Renin-Angiotensin System and the Packed Cell Volume, 
in Nom»otensive Wiatar and Spontaneously Hypertensive 
Rets. Direction of arrow indicates direction of change 
as compared to control: an inclined arrow indicates a 
slight change, a horizontal arrow no difference.
PARAMETER NORMOTENSIVE SPONTANEOUSLY
HYPERTENSIVE
Mean Arterial 
Pressure T 1
Heart Rate — 1
Cardeac Output T r
Stroke Volume T t
Total Peripheral 
Resistance — i
Renal Blood flow 1 i
Renal Vascular 
Resistance T t
Plasma Renin 
Activity t r
Plasma Renin 
Concentration X
Renal Renin 
Concentration 1 X
Packed Cell 
Volume i l
TABLE 6.6 Th» Eff «cf o f  Single P.O. Do«« of Captopril (3Qmg p r  kg) 
on Hae»odynam ic» and th« Packed C»ll Volume of Oestrogen 
Tr»»t»d Mormotensiv« Rata. Legend as described in Table6 .X
PARAMETER
SALINE DOSED 
CONTROLS 
to - 7)
CAPTOPRIL 
DOSED 
(n - 8 ) TEST
Mean Arterial 
Pressure 
mm Hg
151:
150-167
131 - • I • 3.07 ••
Heart Rate 
beata per min 395 - 22 406 - 22 P - 0.67 NS
Cardiac .Output 
ml min k#-1 315 - 59 399 - 169 P - 0.76 MS
Stroke Volume 
ml beat-* kg-1 0.7» - 0.13 0.97 i 0.37 P - 0.65 MS
Total Peripheral 
Resistance
dyn c«-Ssec-lkg-l
41,574 1 8,361 31,131 - 6,933 P - 3.61 MS
Renal Blood Plow 
ml min"1 *-X 5.98 - 0.94 6.24 - 0.80 P - 13.26 ••
Renal Vascular 
Resistance
dyn c»~S«ec—lkg-1
2,157 - 375 1,299 - 149 P - 19.00 •••
Packed Cell 
Volume 
%
28.9 - 1.6 28.6 - 1.4 P - 0 NS
TABLE 6.7 Th« Eff «et« of a single P.O. Do«« of Captopril (30wg p t  kg) 
on Haesodyna»tc« and th« Packed C«ll Vola—  of Oestrogen 
Tr««t«d Spont«n«ou»ly Hypertensiv« R«t». Legend es described 
in T«bl«6 .1
PARAMETER
SALINE DOSED 
CONTROLS 
(a • 5)
CAPTOPRIL 
DOSED 
(n ■ 5)
TEST
Mean Arterial 
Pressure 
ma Hg
154 1 14 141 t 22 r - 1.02 NS
Heart Rate 
beats per sin. 331 - 35 355 - 27 F - 1.05 NS
Cardiac Output 
■1 ain”! kg-1 363 - 100 319 - 31 F - 0.60 NS
Stroke Voluae 
ml beat-1 kg-1 1.09 - 0.24 0.90 - 0.12 F - 1.96 NS
Total Peripheral 
Resistance
dyn ca-5sec_lkg“l
35,040 1 7,595 30,270 - 5,439 •n a o a
Renal Blood Flow 
ml min-1 g-1 6.24 - 0.00 10.63 - 0.61 F - 65.69 •••
Renal Vascular 
Resistance
dyn cs-5««c“lkg-l
20,030 - 435 1,064 - 165 F - 15.94 ••
Packed Cell
Voluaeft 27.0 ~ 1.0 20.0 - 0.6 F - 0.56 NS
TREATED
Figure 6-1 The Effects of lOwg of Oestrone Acetate on the Renal Blood
Flow (RBF), Renal Vascular Resistance (RVR) and Mean Arterial 
Pressure (WAP) of Spontaneously Hypertensive Rats
TREATED
Figure 6» 2 The Effects of lOmg of Oeatrone Acetate on the Plasma Renin 
Activity (PRA) and Packed Cell Volume (PCV) of Spontaneously 
Hypertensive Rats
VEHICLE
CONTROLS
Figure 6.3 The Effects of Captopril (P.0. -3Qmg per Kg) on the Renal Blood 
Flow, Renal Vascular Resistance and Mean Arterial Pressure of 
Normotensive Wistar Rats which had Received lOmg of Oestrone
Acetate
VEHICLE
CONTROLS
Figure 6 .4 The Effects of Captopril (P.0. - 3Qmg per kg) on the Renal Blood 
Flow, Renal Vascular Resistance and Mean Arterial Pressure of 
Spontaneously Hypertensive Rats which had Received lOmg of Oeetrone
Acetate
to above. This observation say be accounted for by the fact that 
the plasma renin concentrations noted in unmani pula tad 
Sprague-Dawley rats were far greater than the values recorded for 
unmanipulated WKY. Since the radioimmunoassay used to measure 
this variable was developed using Sprague-Dawley rats, it may not 
have been sensitive enough to detect a decrease in renin 
concentration in WKY. On the other hand, failure to suppress 
renin secretion in the presence of an increase in circulating 
angiotensin 11 has been considered by Saruta, et al (174) to be a 
causal factor leading to the establishment of oestrogen- 
associated hypertension. An impairment of the negative feedback 
relationship between circulating angiotensin II and renin 
secretion may therefore contribute to the development of the 
increased arterial pressure noted in WKY after oestrogen 
treatment. Consistent with this hypothesis is the observation 
that WKY rats exhibited a larger mean rise in arterial pressure 
in response to oestrogen treatment than did Sprague-Dawley rats 
(♦ 20 v. ♦ 16 mm Hg).
The physiopathological importance of changes in the 
renin-angiotensin system to alterations in haemodynamics in 
oestrogen treated normotensive Sprague-Dawley and WKY rats appear 
to be essentially similar. The findings from chapter 3 suggested 
that an oestrogen-induced stimulation of the renin-angiotensin 
system was involved in establishing aberrations in both systemic 
and renal haemodynamics, although no definate conclusions 
concerning causation could be drawn from these findings. In the 
present study, captopril returned the renal blood flow of rats 
with an oestrogen-induced reduction in renal blood flow to the 
pretreatment level, through a decrease .irr renal vascular 
resistance. This observation provides good evidence to support 
the hypothesis that an increase in the concentration of
99
angiotensin II in the intrarenal circulation was the principal 
event leading to the establishment of a reduced renal perfusion 
in the oestrogen treated normotensive rat. The reduction in 
arterial pressure noted in WKY rats after captopril 
administration clearly demonstrates the involvement of 
angiotensin II in the maintenance of the hypertension noted in 
these animals. The fact that the arterial pressure of these 
captopril treated rats mss still significantly larger than the 
pressure noted in non-oestrogen treated animals reinforces the 
concept outlined previously, that oestrogen-associated 
hypertension is multifactorial in nature - the other major factor 
to be identified by this investigation being an expanded plasma 
volume.
The SHR exhibited a fundamentally different blood pressure 
response to oestrogen treatment compared to its normotensive 
counterpart. In the SHR, blood pressure did not become 
elevated, but actually fell after oestrogen treatment. This 
finding does not agree with previous reports, which have shown a 
rise in blood pressure in genetically hypertensive rets with 
oestrogen (171,177). However, a single author, using the New 
Zealand strain of genetically hypertensive rat, has reported this 
finding. In the only published report using SHR, Hoeg, et al 
(178) have reported that chronic administration of oestrogen to 
young SHR, for a period of 8 weeks, reduced the level of 
hypertension attained. Whilst this report is consistent with the 
present finding, it is unlikely that oestrogen attenuated the 
development of hypertension in the SHR used in this study. The 
hypertension of these animals, at approximately 20 weeks of age, 
is well established, will increase only marginally with advancing 
age, and not at all over a period of 10 days (168).
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The effect of oestrogen on the blood pressure of SHR therefore 
almost certainly reflects en effect of the steroid on established 
hypertension.
The reduction in mean arterial pressure noted in SHR after 
oestrogen treatment took place in spite of en increase in 
cardiac output. As for WKY, this increase mas presumably due to 
an expanded plasma volume - consequent to oestrogen-mediated salt 
and water retention (175,176). The fall in arterial pressure 
must therefore have been the result of the observed reduction in 
peripheral vascular resistance. This reduction occurred in spite 
of an increase in plasma renin activity - which might have been 
expected to promote on increase in vascular resistance. This 
situation is in contrast to that encountered in WKY, where 
peripheral vascular resistance remained unchanged in the presence 
of an increased cardiac output. Here, elevated plasma renin 
activity probably prevented a compensatory fall in peripheral 
vascular resistance. Token together, these findings suggest 
that the different blood pressure response to oestrogen 
treatment, between SHR and WKY, may reflect in part a decline in 
the responsiveness of peripheral resistance vessels to 
angiotensin II in the spontaneously hypertensive animal.
Support for this hypothesis may be derived from the reported 
observation that the SHR exhibits a reduced vasoconstrictor 
response when subjected to acute haemorrhage (182). Similarly, 
hypertensive humans have been reported to have abnormalities in 
responsiveness of the renin-angiotensin system (179,180). 
including a blunted vascular response to renin (181).
The hypothesis outlined above, may well account for a 
reduction in peripheral vascular resistance in the presence of
91
an increased plasma renin activity. It cannot, however, explain 
the fact that the reduction in peripheral vaacular resistance 
noted in oestrogen treated SHR was to such a degree that it 
resulted in a fall in arterial pressure. Two possible 
mechanisms may explain this observation. Firstly, the 
administration of oestrogen to SHR might have induced a marked 
increase in systemic vasodilator substances. In this context, 
oestrogen has been shown to enhance the vascular prostaglandin 
synthesis, either through a direct stimulatory effect (44-46), or 
through its effect on the renin-angiotensin axis (185). Further, 
genetically hypertensive rats exhibit an enhanced vasodepressor 
response to intravenous infusion of both prostaglandin precursors 
(183) and prostaglandins (184) compared to their normotensive 
counterparts. Moreover, experiments undertaken in this 
laboratory have shown that chronic inhibition of prostaglandin 
synthesis can prevent a fall in arterial pressure in the 
oestrogen treated SHR (C.Stonier - personal communication). 
Secondly, although there are no data from the SHR, an increase in 
peripheral venous distensibility, resulting in a loss in venous 
tone, has been reported in women ingesting oestrogen-containing 
oral contraceptives (186).
Collectively, the data described above, indicate that the 
reduction in arterial pressure noted in the SHR after oestrogen 
may have been the result of prostaglandin-mediated vasodilation 
in the presence of peripheral arteriolar hyporeactivity to 
angiotensin II, and/or a direct effect of oestrogen on peripheral 
arterioles, resulting in a loss in vascular tone.
In contradistinction to the marked differences in peripheral 
haemodynamic responses between oestrogen.treated WKY and SHR, the 
intrarenal response of the two strains of rat was
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similar, both showing a reduction in renal blood flow with 
oestrogen. Likewise, these reductions in renal perfusion were 
both due to an increased plasma renin activity, which led to an 
increase in renal vascular resistance. This proposition is 
supported by the observation that administration of captopril to 
oestrogen treated WKY and SHR resulted in a marked reduction in 
renal vascular resistance in both strains, thereby increasing 
renal blood flow. As for WKY therefore, an increased 
concentration of angiotensin II in the intrarenal circulation 
appears to be the causal factor responsible for a reduction in 
renal blood flow in the SHR after oestrogen treatment.
It was of interest to note that in the oestrogen treated SHR, 
unlike WKY, captopril increased renal blood flow to a level which 
was significantly greater than that noted in non-oestrogen 
treated rata. This effect may have occurred as a result of the 
bradykinin potentiating property of captopril (152), and is 
consistent with the reported increase in sensitivity to the 
vasodepressor effect of the antihypertensive prostaglandin 
endocrine system, seen in the SHR compared to its normotensive 
counterpart (183, 184).
From the oestrogen-induced changes in haemodynamics 
described above, it is clear that oestrogen has exerted opposite 
effects on peripheral and renal resistance vessels in the SHR. A 
fall in peripheral vascular resistance may have resulted from a 
stimulatory effect of oestrogen on prostaglandin-mediated 
vasodilation of peripheral resistance vessels, in the presence of 
a reduced vascular responsiveness to angiotensin II. One might 
anticipate that this effect would also lead to a fall in renal 
vascular resistance. Clearly this was not the case. The renal 
vasculature is, however, especially sensitive to the
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vasoconstrictor effect of angiotensin II (6). Moreover, whilst 
prostaglandins have been found to exhibit potent vasodilatory 
properties in several species, including man, anomalous responses 
have been observed in the rat. In this species, whereas 
prostaglandins vasodilate peripheral resistance vessels, they 
appear to vasoconstrict the renal vasculature (187). Indeed, 
McGiff and Quilley (188) feel that this difference constitutes 
the basis for rejection of the genetically hypertensive rat as a 
suitable model of human hypertension. In the SHR therefore, a 
reduction in the responsiveness of peripheral blood vessels to 
angiotensin II may not extend to the hypersensitive renal 
vasculature, in which prostaglandins may act as vasoconstrictors. 
These observations may explain what, at first glance, appear to 
be divergent vascular resistance changes.
In conclusion, oestrogen has been found to induce a 
reduction in renal blood flow in both WKY and SHR. This 
reduction appeared to be the result of angiotensin II- mediated 
constriction of renal resistance vessels in both strains of rats. 
Oestrogen exerted prohypertensive and antihypertensive effects in 
WKY and SHR respectively. This differing circulatory response 
was due, in part, to angiotensin II - mediated vasoconstriction 
in WKY, and a reduction in peripheral vascular resistance in SHR. 
It has been suggested that this latter effect was the result of 
prostaglandin-mediated vasodilation of peripheral resistance 
vessels in the presence of a reduced vascular responsiveness to 
angiotensin II.
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Chapter 7
THE EFFECTS OF PHOSTAGLAICIM SYNTHESIS INHIBITION OH RENAL AMD 
SYSTEMIC HAEMODYNAMICS IN NORMOTENSIVE AND SPONTANEOUSLY
HYPERTENSIVE RATS AFTER OESTROGEN TREATMENT
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7 .1 IWTHOPUCTIOH
The contribution of prostaglandins to the Modulation of ranal 
haemodynamics and blood pressure control under both normal 
clrcumstancea (18, 19, 31) and a number of physiopathological 
states, such as sodium deprivation (27) and hypertension (32), 
has been described during the course o f  this Investigation. In 
the SHR, an Increased elaboration of vmsodilatory prostaglandins 
"•y be evoked In response to the hypertensive state. Thus under 
normal circumstances. Inhibition of prostaglandin synthesis has 
no effect on arterial pressure In WKY, whereas it results In an 
increase In arterial pressure In SHR (192). The findings from the 
preceding chapter suggest that prostaglandin synthesis may also be a 
major determinant of blood pressure in the SHR during oestrogen 
treatment.
Pharmacological interruption of prostaglandin synthesis by 
aspirin-like drugs, such as indomethacin and meclofenamate. Is 
the standard technique used to investigate the physiological role 
of prostaglandins. These substances inhibit the action of tissue 
cyclo-oxygenase (see p.7), thereby preventing the formation of 
prostaglandins (189).
The objective of this study therefore, was to investigate 
the contribution of prostaglandins to cardiovascular function in 
the oestrogen treated SHR and WKY rat, by use of the 
prostaglandin synthesis inhibitor, indomethacin.
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7.2 METHODS
BxperlaenUl Procedure
Oe at rone acetate in ethyl oleate (4 ag per al) was uaed to give 
subcutaneous injections of 1 mg of oestrogen per day for 10 days to 
both SHR (160-200 g) and WKY (188-279 g).
24-hours after receiving their last injection of oestrogen, 
rats were prepared for experimental analysis as described in 
chapter 2. Rats were infused intra-arterially via tha femoral 
catheter, with either indomethacin (total dose- 6 mg per kg of 
body weight) or vehicle (total voluae- 0.340 al) ovar a 10 minute 
period. Approximately 45 minutes after initiation of infusion of 
either indoaethacin or vehicle, haemodynamic variablaa and the 
packed cell volume were measured as described in chapter 2. 
Preparation of Indomethacin
Indomethacin has a low aolubillt^n w,t,r• ,0 
preparation of the drug by dissolving it in an alkali is necessary 
where the intravenous route of administration ia to be used. 
However, indomethacin is unstable in alkaline solutions, and 
special attention must therefore be given to preparation of the 
drug (190).
Indomethacin (Sigma) was dissolved in 0.05 M sodium 
carbonate at room temperature, and the pH rapidly adjusted to 
approximately 7.5 with 1 M hydrochloric acid. The solution was 
immediately split into the required number of 3 ml aliquots, 
frozen, and stored in the dark at -20° C for no longer than 20 
days. A solution of sodium carbonate (0.05 M, pH 7.5 and stored 
at -20° C) acted as vehicle. Aliquots of the drug or vehicle 
were warmed to 37° C immediately prior to infusion.
It has been shown that indomethacin preparations of the type 
described above are stable at —20 C for at least lOO days,and at
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room temparature for at least 1 hour (190).
The doae of indomethacin selected for this study (6 eg per kg) 
has been shown to cause significant inhibition of renal prostaglandin 
synthesis in the rat 090% reduction in urinary PC excretion (191)).
7.3 RESULTS
Effects of Indoswthmcln in Oestrogen Treated SHR (Table 7.1 and 
Figure 7.1)
Systealc Haemodynamics
Administration of indomethacin had no effect on mean arterial 
pressure (167 - 9 v. 158 - 7 mm Hg), cardiac output (340 - 59 v.
334 - 59 ml mln“Xkg”X) or total peripheral resistance (40,728 
- 7,377 v. 39,420 - 7,215 dyn cm"5sec”1kg"X).
Renal Haemodynamics
Renal blood flow increased from 5.35 - 0.19 to 7.14 - 1.16 
ml min_1g_1 (p<0.05), and renal vascular resistance decreased 
from 2,493 - 149 to 1,847 1 386 dyn cm"5aec"1kg_1 (p<0.05) after 
indomethacin.
Packed Cell Volume
The packed cell volume was not influenced by administration 
of indomethacin (27.3 - 1.2 v. 27.3 1 1.6 %).
Effects of Indomethacin In Oestrogen Treated WHY (Table 7.2)
Systemic Haemodynamics
Mean arterial pressure (131 - 7 v. 137 - 7 mm Hg), cardiac 
output (309 - 67 v. 332 — 33 ml min”Xkg“X) and total peripheral 
resistance (36,806 - 10,892 v. 33,465 - 4,343 dyn cm_5sec"1kg”1) 
remained unchanged after indomethacin.
Renal Haemodynamics
Renal blood flow increased from 5.63 - 1.27 to 7.16 - 0.55 
ml min-1g”X, and renal vascular resistance decreased from 
2,097 * 802 to 1,539 *■ 135 dyn cm-5sec“1kg- 1 with indomethacin.
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However, neither of these changes achieved statistical significance. 
Packed Cell Volisae
Infusion of indosMthacin did not influence the packed cell 
volume (31.6 ♦ 1.2 v. 31.6 ♦ 0.7%).
7 .4 DISCUSSIOW
The findings fro* this study have demonstrated that in the 
oestrogen treated rat, inhibition of prostaglandin synthesis has 
no effect on arterial pressure in either WKY or SHR. This inhibition 
did, however, result in a significant increase in renal blood flow 
in SHR. The same direction of change in renal blood flow also 
occurred in WKY.
The findings froei the preceding chapter demonstrated that a 
reduction in arterial pressure occurred in the SHR after oestrogen 
treatment. This reduction was due to a marked decrease in peripheral 
vascular resistance, which took place in spite of an increased plasma 
renin activity. This observation, coupled with both the known 
stimulatory effect of oestrogen on vascular prostaglandin synthesis 
(44-46), and the enhanced sensitivity to prostaglandins shown by 
SHR compared to WKY (184), suggests that the reduced arterial pressure 
noted in SHR after oestrogen may have been the result of prostaglandin- 
mediated vasodilation in the presence of peripheral arteriolar 
hyposensitivity to the vasoconstrictor action of angiotensin II.
The present finding, that administration of indomethacin had no effect 
on the arterial pressure of oestrogen treated SHR, does not, however, 
agree with the hypothesis outlined above. This lack of effect of 
indomethacin may well be accounted for by the acute nature of the 
dosing regime employed during the current study. Indeed, work done 
in these laboratories has shorn that the simultaneous, chronic 
administration of oestrogen and indomethacin (subcutaneously) over a 
period of 10 days, prevented a fall in arterial pressure in SHR 
(C. Stonier: personal communication).
TABLE 7.1 The Effect» of Indoaethacln (6 ag per kg of body wight)
on Renal end Systealc Haemodynamics In the SHR after
Peetrone Acetate (1 mg per day for 10 deye) Treatment.
Values are presented as a mean 1 95* confidence Halts. 
Data have been analysed using a one way ANOVA. The 
probability value of the teat statistic- F la Indicated 
in the test coluan.
PARAMETER VEHICLE INFUSED INDOMETHACIN TEST
CONTROLS 
(n ■ 6 )
INFUSED
(n - 6 )
Mean Arterial 
Pressure 
mm Hg
167 - 9 1 5 8 - 7 F - 2.38 NS
Heart Rate 
beats per aln.
337 1 17 302 - 25 F - 5.04 •
Cardiac Output 
al aln-1kg“ 1
340 - 59 334 - 59 F - 0.02 NS
Stroke Volume 
al beat-1kg- 1
1.02 - 0.24 1 . 1 1  - 0.16 F - 0.41 NS
Total Peripheral
Resistance
dyn ca-5sec-1kg“’ 1
40,728 - 7,377 39,420 - 7,215 F - 0.06 NS
Renal Blood Flow 
al aln'^g” 1
5.35 - 0.19 7.14 - 1.16 F - 8 .86 v
Renal Vascular 
Resistance
dyn ca-5sec-1kg- 1
2.493 1 149 1,847 - 386 F - 9.36 •
Packed Cell Volume 
X
27.3 i 1.2 27.3 1 1.6 F - 0.00 NS
TABLE 7.2 The Effect« of Indoswthacln (6 as per kg body wight) 
on Renal end Systemic Haemodynamics In WKY Rate After 
Peetrone Acetate (1 eg per dey for 10 deye) Treatment. 
Legend as described in Table 7*1*
PARAMETER VEHICLE INFUSED INDOMETHACIN TEST
CONTROLS 
(n ■ 6 )
INFUSED
(n - 6 )
Mean Arterial 
Pressure 
mm Hg
131 i 7 137 1 7 F - 1.23 NS
Heart Rate 
beats per min.
400 - 14 414 - 8 F - 3.06 NS
Cardiac Output
. « -1. - 1  ml min kg
309 - 67 332 - 33 F - 0.35 NS
Stroke Volume 
ml beat_1kg 1
0.78 ~ 0.18 0.80 - 0.08 F - 0.07 NS
Total Preipheral 
Resistance
-5 -1. -1 dyne cm sec kg
36,806 - 10,892 33,465 - 4,343 F - 0.31 NS
Renal Blood Flow
i 4 -1,. - 1ml min kg
5.63 - 1.27 7.16 ~ 0.55 F - 4.62 NS
Renal Vascular 
Resistance
-5 -1. -1 dyn cm sec kg
2,097 - 802 1,539 ~ 135 F - 1.81 NS
Packed Cell
Volume
X
31.6 - 1.2 31.6 - 0.71 F - 0.00 NS
INFUSED INFUSED
CONTROLS
Figure 7.1 The Effects of Indomethacin (6 mg per kg BW) on the Renal Blood 
Flow (RBF) Renal Vascular Resistance (RVR) and Mean Arterial 
Pressure (MAP) of Spontaneously Hypertensive Ra^ -s Which Had 
Received 10 mg of Oestrone Acetate
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Inhibition of prostaglandin synthesis resulted in an increase 
in renal blood flow, due to a decreased renal vascular resistance, 
in oestrogen treated WKY and SHR. This effect is not what one aight 
have anticipated after the elimination of a vasodilator/ substance 
froa the renal circulation. It is, however, consistent with the 
previously described action of proataglandins such as prostaglandin 
E2(187, 193), and thromboxane A2(194), as renal vasoconstrictors in 
the rat. The vasoconstrictor action of these substances aay be 
mediated by either a direct effect on renal vasculature (194) or 
through a stimulatory effect on renin release (25,26, Tig. 1.4).
From the preceding chapter, it will be remembered that 
Inhibition of angiotensin II formation, by use of the angiotensin 
converting ttizyme inhibitor, captopril, restored the increased renal 
vascular resistance of oestrogen treated WKY and SHR to the pretreat­
ment level. If prostaglandins were exerting a prominent vasocon­
strictor action on the renal vasculature of the above animals, in 
which any effect of prostaglandins on renin release (and subsequent 
generation of angiotensin II) had been removed, one aight have 
expected that the renal vascular resistance of these animals would 
have remained at least somewhat elevated compared to their non­
oestrogen treated controls. This would be especially so, given the 
stimulatory effect of captopril on prostaglandin production in man 
(195, 196) and more relevantly, the glomeruli of the rat (197). This 
was not the case however, indicating that the vasoconstrictor action 
of prostaglandins reported in this study, was not the result of a 
direct effect of these substances. On the other hand, there is a 
growing body of evidence to indicate that in the healthy condition, 
and under certain diseased states, prostaglandin biosynthesis may be
central to the control of renin release. This topic has been 
extensively reviewed by Jackson, at al (198). Of particular 
Interest to this atudy are the reports which have shown that the 
administration of indomethacin can affect a reduction in blood 
pressure under conditions in which arterial pressure is maintained, 
in part, by elevated levels of plasma renin activity. This effect 
of indomethacin is associated with a reduction in plasma renin 
activity (27,199,200). Although plasma renin activity was not 
measured in the present study, the observation from Chapter 6 , that 
both oestrogen treated WKY and SHR failed to suppress plasma renin 
concentration in the presence of an elevated plasma renin activity 
is consistent with a stimulatory effect of prostaglandins on renin 
release in the oestrogen treated rat.
Taken together, the findings described above suggest that a 
prostaglandin-dependant pathway is involved, in part, in the angiotensin 
Il-oediated reduction in renal blood flow which haa been identified in 
both oestrogen treated WKY and SHR, by the experiments described in 
the preceding chapter.
In conclusion, inhibition of prostaglandin synthesis has been 
found to have no effect on the arterial pressure of oestrogen
treated SHR. This finding fails to support other evidence which 
indicates that prostaglandin-mediated vasodilation of peripheral 
resistance vessels ia responsible for a reduction in arterial pressure 
in the SHR after oestrogen. However, differences in the indomethacin 
administration protocol between these sets of data may go some way 
to explain the apparently conflicting findings.
Prostaglandin synthesis inhibition has also been found to 
result in a reduction in renal vascular resistance in oestrogen 
treated WKY and SHR. It has been suggested that this apparent
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renal vasoconstrictor action of prostaglandins was, in fact. 
Mediated via a stimulatory effect of prostaglandins on renin 
secretion. A prostaglandin dependant pathway may therefore 
contribute to the angiotensin II-sMdiated constriction of the 
renal vasculature which has been identified in both WKY and SHR 
after oestrogen treatment.
102
Chapter ft
THE INFLUENCE OF DIETARY SODIUM RESTRICTION OH RENAL AW) SYSTEMIC
HAEMODYNAMICS IN RATS RECEIVING INJECTIONS OF OESTROGEN
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8.1 INTRODUCTION
Th* reciprocal relationship between sodium intake and renin 
secretion is well documented (132,133). An alteration in dietary 
sodium intake is therefore a commonly used method of changing 
renin-angiotensin activity. This manoeuvre alters the transport 
of sodium in the distal tubule of the nephron and thus renin 
release (134). Dietary sodium restriction results in a marked 
increase in plssma renin activity (135). Conversely excessive 
sodium intake suppresses plasma renin activity (136)«
In spite of causing an increased plasms renin activity, 
dietary sodium restriction characteristically has no major effect 
on either arterial pressure or renal blood flow in the 
normotensive state, although a reduction in both arterial 
pressure (137) and renal blood flow (138) have been recorded.
There is, however, clesr evidence demonstrating the dependency of 
these haemodynamic variables, on the endogenous level of 
angiotensin II, in the salt-deplete state. This evidence is 
based on the reports that pharmacological interruption of the 
renin-angiotensin system, in salt deprived animals, results in a 
fall in arterial pressure (138, 139) and a rise in renal blood 
flow (138-140).
Although there is a body of data associating excess salt 
intake with hypertension (141), definitive proof is, at the 
present time lacking. In this context, dietary sodium 
restriction has been useful in reducing the blood pressure of 
hypertensive subjects (142). Recently however, the merits of the 
marginal hypotensive effect of this manoeuvre have been 
questioned (143).
The objective of this study therefore, was to investigate 
the effect of the chronic physiological challenge of dietary
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sodium restriction - on renal and eystemic haemodynamics - in 
rata receiving oestrogen. This approach presents an opportunity 
to assess the effectiveness of the control of the renal 
circulation whan challenged by a combination of two manoeuvres, 
both capable of stimulating the renin-angiotensin system. The 
findings of this study may also help to define the benefits, if 
any, of a low sodium diet, to women who are susceptible to 
oestrogen-associated hypertension.
8 . 2  METHODS
Adult female Sprague-Dawley rats (Nottingham Universityi 190 
- 240g), housed at 21 ♦ 1°C, were used throughout the study. 
Animals were fed either a normal sodium (0.34%) or low sodium 
(0.007%) diet (SOS, England), and drank tap water and distilled 
deionised water ad libitim, respectively. Oestrone acetate in 
ethyl oleate (A mg per ml) was used to give subcutaneous 
injections of 1 mg oestrogen on alternate days. Oestrogen 
treatment snd dietary sodium restriction were applied to five 
experimental groups of rats, according to the following schedule: 
Experimental Duration of Oestrogen Type and Purataion Qf
Group
1 
2
3
4
5
Tr ?9(9mgn_l -  days
10
20
Diet - days 
Normal Na - 10 
Normal Na - 10 
Normal Na - 20 
Low Na - 10
Normal Na - 10 
followed by 
Low Na - 10
The control animals for oestrogen treated groups 2 and 3
were maintained on the normal sodium diet, and received the 
appropriate injection of vehicle alone.
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As in preceding chapters, the injection of vehicle alone did 
not alter any of the parameters under study (Tables 8.1 and (*.2). 
Data from the vehicle-injected animals and group 1 have therefore 
been pooled, and form the control group for the experimental 
groups 2,3 and 4. The effect of dietary sodium restriction on 
oestrogen treated animals has been assessed by comparing groups 3 
and 5.
24-hours after completing the schedule, animals mere 
prepared for experimental analysis. Haemodynamic variables, 
renin-angiotensin system parameters (including both trypsin- and 
acid-activable renin) and the packed cell volume of blood samples 
were measured as described in previous chapters.
8.3 RESULTS
Effect of Oestrogen Treatment
Haemodynamics (Tables 8.3 and 8.4)
Mean arterial pressure was elevated after 10 days of 
oestrogen treatment (p <  0.03), with no significant changes in 
either cardiac output or total peripheral resistance. Arterial 
pressure increased further after 20 days of oestrogen (p<
0.001): this pressure being significantly greater than that 
recorded after 10 days of oestrogen (p< 0.03). Whilst cardiac 
output remained unchanged after 20 days of oestrogen, total 
peripheral resistance was elevated (p< 0.01).
Whereas renal vascular resistance was unchanged after 10 
days of oestrogen, it became elevated after 20 days of treatment 
( p< 0.03). Renal blood flow was not affected by oestrogen.
Active Renin (Tables 8.5 and 8.6)
Plasma renin activity was unchanged after 10 days of 
oestrogen, but was increased after 20 days (p< 0.01).
Plasma and renal renin concentrations were decreased, both 
after 10 ( p <  0.01) and 20 days (p< 0.001) of oestrogen treatment.
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Inactive Renin (fables 8.* “ 0.7)
Inactive plasma renin was increased after both 10 (p <  0.001) 
and 20 deye ( p< 0.05) of oestrogen treatment.
Inactive renal renin was unchanged after 10 deys of 
oestrogen, and decreased after 20 deys of treatment (p< 0.05). 
Pscked Cell Volume (Tables 0.3 snd 8.4)
The packed cell volume was unchanged after 10 deys of 
oestrogen, but decressed after 20 days of treatment ( p <  0.001).
In summary, a rise in mean arterial pressure was noted in 
rats after 20 days of oestrogen treatment. This rise was 
accompanied by an increase in both total peripheral resistance 
and plasma renin activity, and a fall in the packed cell volume. 
Oestrogen treatment had no effect on renal blood flow. An 
increase in circulating inactive renin was observed in oestrogen 
treated rats.
Effect of Dietary Sodium Restriction 
Haemodynamics (Tables 8.3 and 8.4)
10 days of dietary sodium restriction reduced mean arterial 
pressure ( p <  0.01). Sodium depletion reduced cardiac output (p <  
0.05), but had no effect on total peripheral resistance.
Neither renal blood flow or renal vascular resistance were 
influenced by dietary sodium restriction.
Active Renin (Tables 8.5 and &6)
Whilst plasma renin activity increased with sodium 
restriction ( p <  0.001), both plasma and renal renin 
concentrations remained unchanged.
Inactive Renin (Tables 8.5 - 8.7)
No inactive renin was detected in the plasma of rats fed the 
low sodium diet. Inactive renal renin was not affected by
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sodium restriction.
Pecked Ceil Volume (Tables 8-3 end 8.4)
Dietery sodium restriction did not effect the pecked cell
In summary, 10 days of dietary sodium restriction resulted 
in a marked rise in plasma renin activity. In spite of this 
rise, mean arterial pressure fell, due to a reduced cardiac 
output. Renal blood floe mss not affected by sodium depletion.
No inactive renin was detected in the plasma of sodium deprived 
rats.
Effect of Dietary Sodium Restriction in Rata Receiving Oestrogen 
Haemodynamics (Tables 8.3 and 8 4  and Figure 8.1)
Sodium restriction decreased the mean arterial pressure of 
oestrogen treated rats ( p< 0.05). The arterial pressure of 
these rats was significantly larger than the non-oestrogen 
treated control value (p< 0.05), but similar to the pressure 
noted in rats after 10 days of oestrogen treatment. Cardiac 
output was increased ( p ^  0.05) and total peripheral resistance 
reduced ( p <  0.01) in sodium restricted oestrogen treated rats.
Sodium deprivation had no effect on either the renal blood 
flow or renal vascular resistance of oestrogen treated rats. 
Active Renin (Tables 8.5 and 8.6)
Neither the plasma renin activity nor the plasma and renal 
renin concentrations of oestrogen treated rats were influenced by 
sodium restriction.
Inactive Renin (Tables 8.5 - 8.7)
No inactive renin was detected in either plasma or renal 
cortical tissue of oestrogen treated rats fed the low salt diet.
loa
Packed Cell Volume (Tables 8.3 and 8.4)
Whilst sodium restriction increased the packed cell volume 
of oestrogen treated rata (p< 0.05), the packed cell volume of 
these animals mas significantly smaller than the value noted in 
non-oestrogen treated control rats ( p< 0.001).
In summary, dietary sodium restriction affected a marginal 
fall in mean arterial pressure and a small increase in the packed 
cell volume of oestrogen treated rats. The renal blood flow of 
oestrogen treated rats was not affected by sodium restriction, 
khilst sodium deprivation did not affect the plasma renin 
activity of oestrogen treated rats, it eliminsted inactive renin 
from the plasma of these animals.
8.4 DISCUSSION
The findings from this study have shown that 10 days of 
dietary sodium restriction had no effect on the renal blood flow 
of rats undergoing a 20 day period of oestrogen treatment. This 
sodium restriction did, however, prevent an exacerbation of the 
hypertension noted in oestrogen treated rats. This effect was 
associated with an attenuation of a contracting packed cell 
volume. Whereas sodium restriction affected a marked rise in 
plasma renin activity in non treated rats, it had no influence on 
the plasma renin activity of oestrogen treated animals. No 
inactive renin could be detected in the plasma of both non 
treated and oestrogen treated rats fed the low sodium diet.
Dietary sodium restriction did not affect either the level 
of renal perfusion, or the autoregulation of renal blood flow in 
response to a fall in perfusion pressure - in both non treated 
and oestrogen treated rats. Similarly, oestrogen treatment had 
no effect on renal blood flow. This latter observation is in 
contrast to the findings from chapter 3, where a fall in renal
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OESTROGEN AND OESTROGEN AND
NORMAL SODIUM LOW SODIUM
DIET DIET
Figure fl.l The Effects of Dietary Sodium Restriction on the Renal
Blood Flow. Mean Arterial Pressure and Packed Cell Volume 
of Oestrogen Treated Rats. Both groups of rats received 
lmg oestrone acetate on alternate days for 20 days. The 
low sodium diet group of rats were fed a low sodium diet 
for the latter 10 days of oestrogen treatment.
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blood flow with oestrogen was noted in group B (10 mg oestrone 
over a period of either 10 or 20 days). However, out of 
necessity, different oestrogen dosing regimes have been employed 
in these two studies.
In non-oestrogen treated rats, dietary sodium restriction 
resulted in a reduction in arterial pressure, due to a fall in 
cardiac output. These findings are in agreement with published 
data concerning the rat (144,145). The fall in arterial pressure 
mentioned above may have contributed to the marked increase in 
plasma renin activity which was noted in these animals. It was 
of interest to note that in spite of the changes mentioned above, 
the packed cell volume of non-oestrogen treated rats fed the low 
salt diet was normal suggesting that this manoeuvre had, if 
anything, only a minimal effect on extracellular fluid volume in 
these animals.
In oestrogen treated rats, dietary sodium restriction 
prevented the rise in blood pressure which took place during the 
latter 10 days of oestrogen treatment. This effect of sodium 
deprivation was associated with an attenuation of a contraction 
in the packed cell volume. The arterial pressure and packed cell 
volume of oestrogen treated rats fed the low salt diet were, 
however, significantly larger and smaller respectively, than the 
values recorded for these variables in non-oestrogen treated 
rats. Taken together, these data support the hypothesis that the 
oestrogen-induced hypertension encountered in this investigation 
is mediated in part by a powerful antinatriuretic action of 
oestroger\ which in turn leads to fluid retention and arterial 
overfill. Further, whilst a low sodium diet may be successful in 
preventing an exacerbation of oestrogen-associated hypertension, 
it would appear to be of only minimal benefit as a form of 
antihypertensive therapy.
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The present findings ciesrly show that whereas dietary 
sodium restriction csused s marked rise in the plasms renin 
activity of ndn trested rets, it hsd no effect on the plssma 
renin sctivity of oestrogen trested animals. Oestrogen and 
sodium restriction stimulate plasma renin activity by different 
pathways - oestrogen increases renin substrate synthesis (39) and 
sodium restriction increases renin release (134). The former path* 
way initiates a powerful negative feedback inhibition on renin 
secretion, as evidenced by a marked reduction in both plasma and 
renal renin concentrations in all the oestrogen treated groups of 
rats used in this study. This effect of oestrogen may explain 
the failure of sodium restriction to cause an increase in plasma 
renin sctivity in the oestrogen treated rat.
Inactive renin was absent from the plasma of both groups of 
rats which were fed the low sodium diet. In non-oestrogen 
treated rats a marked rise in plasma renin activity was noted in 
association with the disappearance of plasma inactive renin.
This observation is in agreement with the findings from the 
preceding chapter which, it was suggested, indicate that 
inactive plasma renin is a direct precursor of active plasma 
renin. Moreover, there is evidence to indicate that conversion 
of inactive to active plasma renin is a physiological event, 
mediated intrarenally (119) by kallikrein Q08)..
In the salt-deplete state, it will be remembered, renal 
perfusion is highly dependant on angiotensin II (140). In this 
situation, enhanced intrarenal production of both kallikrein (28) 
and prostaglandins (27)antagonise the pressor action of 
angiotensin II, and thereby serve to modulate renal
I l l
haemodynamics. In the sodium-deplete state therefore» 
circulating inactive renin may repreaent a significant 
post-secretory source of renin, which ia recruited intrarenally 
by kallikrein, in order to maintain renal perfusion through the 
pressor action of angiotensin 11. Consistant with this 
hypothesis is the absence of inactive renin in the plasma of rats 
fed the low sodium diet.
In conclusion, although both oestrogen treatment and dietary 
sodium restriction were found to increase plasma renin activity 
in the rat when administered independently, renal haemodynamics 
were found to be normal in a group of oestrogen treated rats fed 
a low sodium diet, further, sodium restriction had only a 
marginal effect on the hypertension noted in oestrogen treated
rats
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9.1 RESUME OP THE BACKGROUND AHP PURPOSE OF IHVESTIGATIOH
A healthy renal circulation la critical to normal renal 
function. Control of the renal circulation and the Maintenance of 
cardlovaacular homeostasis are linked through a number of common 
intrarenal pathways involving vasoactive compounds and extracellular 
fluid volume regulation. Oeetrogena have the potential to influence 
the renal circulation (and thereby cardiovascular function) - 
principally through their effects on blood pressure, vasoactive 
confounds - particularly angiotensin II, and smooth muscle receptor 
physiology. In spite of this potential, and the widespread use of 
oestrogens for contraceptive purposes, the effect of these steroids 
on the renal circulation has received only minimal attention.
This investigation was undertaken with the objective of assessing 
the connection between oestrogen-induced changes in renal and systemic 
haemodynamics, and the relationship of these changes to alterations 
in intrarenal vasoactive compounds and plasma volume status. This 
multifaceted approach has been achieved by the use of radiolabelled 
microspheres and radioimmunoassay to measure haemodynamic and renin- 
angiotensin variable« respectively, tryptic and acid activation of 
inactive renin, dietary sodium restriction and inhibition of 
both angiotensin II formation and prostaglandin synthesis. Both 
normotensive and spontaneously hypertensive strains of rat have 
been studied.
It need be emphasised that no measurements of circulating 
oestrone concentrations have been made during this investigation.
The amounts of oestrone which have been used are pharmacological, 
and larger than the doses of other types of oestrogens commonly used 
by most workers. The relative impotency of oestrone compared to
114
these other oestrogens (39,201) would, however, be likely to 
result in comparable levels of oestrogenic activity.
9.2 GENERAL DISCUSSION
The findings from chapter 3 of this investigation have 
demonstrated that oestrogen can catse a reduction in renal blood 
flow and an increase in arterial pressure in the normotensive rat. 
Whilst these haemodynamic changes took place independently of one 
another, they were accompanied by marked alterations in both the 
renin-angiotensin system and plasma volume status.
The reduction in renal blood flow described above was due to 
an increased renal vascular resistance in the presence of an 
elevated plasma renin activity. This latter change - which 
probably occurred as the result of a profound increase in renin 
substrate synthesis - suggests that angiotensin II-mediated 
constriction of the renal vasculature was responsible for the 
increased renal vascular resistance. Strong support for this 
hypothesis was provided by the findings from chapter 7 .  Here, 
administration of the angiotensin converting enzyme inhibitor, 
captopril, to WKY rats with an oestrogen-induced reduction in renal 
blood flow, was found to restore renal blood flow to the pretreatment 
level - by reducing renal vascular resistance.
The angiotensin II-mediated vasoconstriction described above 
may have occurred as the result of a general increase in the 
concentration of angiotensin II throughout the circulation, as 
indicated by the observed increased plasma renin activity. However, 
whilst it was found that changes in plasma renin activity were 
reciprocally related to changes in renal blood flow in rats with a 
normal level of renal perfusion, no such relationship was noted
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In rats with an oestrogen-induced reduction In renal perfuaion.
This observation, in conjunction with the fact that oestrogen-induced 
lncreaaea in renal vascular resistance were much greater than those 
noted in peripheral vascular resistance, suggests that there is a 
critical lntrarenal focus for the action of angiotensin IX in the 
oestrogen treated rat. This hypothesis ia in keeping with the 
concept of angiotensin II as a local renal vascular horsone (9-11). 
Angiotensin II is, however, only a single elesent in an intrarenal 
hormonal complex, which includes prostaglandins and kinins. and 
which is concerned with the modulation of renal haemodynamics 
(12,13.18,19,27,28). This investigation provides evidence to 
suggest that oestrogen can disturb the normal equilibrium which 
exists between these intrarenal vasoactive compounds (27,28). This 
effect ultimately leads to inappropriate, angiotensin II-mediated 
constriction of the renal vasculature, thereby reducing renal 
perfusion.
The findings from chapter 4 are consistent with the presence 
of an inactive form of renin in rat plasma - which is of renal 
origin. The inverse relationship which has been recorded between 
inactive and active renin supports the concept that inactive 
renin is a proenzyme precursor for active renin. There is evidence 
to suggest that conversion of inactive to active renin is a 
physiological event (119), mediated intrarenally by Kallikrein 
(108). Inactive renin in plasma may therefore represent a 
significant postsecretory source of renin, which might serve to 
regulate the amount of angiotensin II available to the renal 
circulation. Oestrogens have been reported to activate the 
kallikrein-kinin system (42,43). This observation, coupled with 
the finding that inactive renin was absent from the plasma of rats 
with an oestrogen-induced reduction in renal blood flow, suggests
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that conversion of active to inactive renin was enhanced in these 
animals. In the presence of an elevated concentration of renin 
substrate, the additional intrarenal angiotensin IX thus generated 
would be likely to Increase renal vascular resistance. The findings 
frosi a preliminary study designed to test the above hypothesis indicate 
that acute Inhibition of renal kallikrein activity, through use of the 
serine esterase inhibitor, aprotlnln, did not alter either the renal 
blood flow or arterial pressure of oestrogen-treated normotensive rats.
The findings from chapter 7 have reported an apparently intrarenal 
vasoconstrictor mode of action by renal prostaglandins, in both WKY and 
SHR after oestrogen. Here, Inhibition of prostaglandin synthesis, by 
adsiinistration of indomethacln, resulted in an increase in renal blood * 
flow, through a decrease in renal vascular resistance. This effect of 
renal prostaglandins was, however, probably mediated via a stimulatory 
action of prostaglandins on renin release (and subsequent generation of 
angiotensin II) (198). Support for this hypothesis may be derived from 
the observation that the renal vascular resistance of oestrogen treated 
WKY and SHR given captopril was not even slightly elevated compared to 
pretreatment values. Thus a prostaglandin—dependant pathway might 
contribute in part to the angiotensin II-mediated renal vasoconstriction 
identified in both WKY and SHR after oestrogen.
The experiment described in chapter 5 was designed to evaluate the 
role of angiotensin II in oestrogen-induced haemodynamic disturbances, 
through use of the angiotensin II antagonist - saralasin. However, 
the antagonist was found to exhibit agonistic-like activity in oestrogen 
treated rats, with a particularly marked expression on the renal 
vasculature. Whereas this agonistic activity did not permit any 
conclusions in connection with the primary objective of the experiment, 
it suggests that oestrogen may have an influence on vascular angiotensin 
II receptor physiology in these animals. This proposal is based on the
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reporta which have shown that the agonistic property of saralasin la 
prominhnt in atatea in which the denaity of vaacular angiotensin XI 
receptora ia elevated (150, 154, 162). Oeatrogena can increaae the number 
of angiotenain II receptora, both in the glomeruli of normotenaive rata 
(A. Messenger: personal communication) and in the myometrium (47).
Thus an increase in the density of intrarenal vascular angiotensin IX 
receptors with oes troné would, in the presence of an increaaed level
of endogenous angiotensin II, be likely to increase renal vascular 
reaistance.
Collectively, the findings from this investigation demonstrate 
that the reduction in renal blood flow noted in the normotensive 
rat after oestrogen can be attributed to angiotensin II-mediated 
constriction of the renal vasculature, which was principally due 
to a marked stimulation of renin aubatrate synthesia. Both 
prostaglandin- and kallikreln-dependant pathways may contribute to 
thia angiotensin II—mediated vasoconstriction, which might be magnified 
in the presence of an increase in the density of intrarenal vascular 
angiotensin XI receptors.
The rise in arterial pressure described at the beginning of 
this discussion took place without any ma: ked alteration in either 
cardiac output or total peripheral resistance. This observation 
suggests that both 'volume' and 'vasoconstrictor' factors were 
involved in the maintenance of this hypertension.
Throughout this investigation oestrogen treatment has been 
found to consistently reduce the packed cell volume. This reduction, 
indicative of plasma volume expansion, was probably mediated by 
the salt and water retaining properties of oestrogen (91-93).
Moreover, the observation that changes in the packed cell volume
1 1 8
were reciprocally related to changes in mean arterial pressure is 
consistent with a prominent volixae component in the mediation of 
hypertension. The findings from chapter g have demonstrated that 
dietary sodium restriction had only a minimal effect on the 
packed cell volume of oestrogen treated rats, and was therefore 
of marginal benefit ss a form of antihypertensive therapy in these 
animals.
The involvement of angiotensin II in the maintenance of the 
oestrogen-induced hypertension reported in this investigation 
was demonstrated by the findings from chapter 6. Here, administration 
of captopril to WKY rats with an increase in arterial pressure, 
due to oestrogen pretreatment, was found to reduce arterial pressure.
Taken together, the findings from this investigation indicate 
that the rise in mean arterial pressure noted in the normotensive 
rat after oestrogen, was determined by a combination of plasma 
volume expansion and a renin-angiotensin activity which was 
inappropriately high in relation to plasma volume status.
The findings from chapter 7 of this investigation have demon­
strated that oestrone also has a pronounced effect on renal and 
systemic haemodynamics, the renin-angiotensin system and plasma 
volume status in the SHR. Like its normotensive WKY counterpart, 
the SHR exhibited a reduced renal blood flow after oestrogen 
treatment. Unlike WKY however, the mean arterial pressure of SHR 
dropped after oestrogen. This latter finding is in contrast 
to the reported exacerbation of pre-existing hypertension in 
women ingesting oestrogen-containing oral contraceptives (165,166). 
This observation raises the possibility of an important difference 
in the circulatory response to oestrogen, between the most widely
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used experimental animal model of human easential hypertension, 
end individuals manifesting the disease itself.
The drop in mean arterial pressure, noted in SHR after 
oestrogen, took place in spite of a reduction in the packed cell 
volume, and increases in cardiac output, renal vascular 
resistance and plasma renin activity - all of which might be 
expected to promote an increase in arterial pressure. A marked 
reduction in peripheral vascular resistance was therefore 
responsible for this fall in perfusion pressure. These findings 
suggest that vasodilation of peripheral resistance vessels 
in the presence of a diminished vascular responsiveness to 
angiotensin II was responsible for the drop in arterial pressure. 
This vasodilation may have been mediated by a stimulatory effect 
of oestrogen on vascular prostaglandin synthe*!* (44-46). Support 
for the above hypothesis may be derived from the reported abnor­
malities in the responsiveness of the renin-angiotensin system in 
both the SHR(182) and essentially hypertensive humans (179-181), 
the increased responsiveness to vasodepressor prostaglandins 
exhibited by SHR (184), and the observation that chronic indomethacin 
administration can prevent a fall in arterial pressure in the 
oestrogen treated SHR (C. Stonier: personal communication). The 
findings from chapter 7 of this investigation however, fail to 
support the aforementioned hypothesis. Here, acute administration 
of indomethacin to SHR pretreated with oestrogen, failed to 
affect an increase in the arterial pressure of these rats.
The proposed diminution of the responsiveness of peripheral 
resistance vessels to the vasoconstrictor action of angiotensin II, 
did not extend to the renal vasculature of the oestrogen treated 
SHR. Here, the vascons trie tor action of angiotensin II led to a 
marked increase in renal vascular resistance, which resulted in
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• fall in renal blood flow. Thu*, as for MKY, captopril restored 
the renal blood flow of oestrogen treated SHR by reducing renal 
vascular resistance.
On the basis of the haemodynamic changes reported in this 
investigation, it is evident that oestrone can disturb normal 
cardiovascular function in the rat. Moreover, it is clear that the 
renal circulation ia a major sit* for this effect of oestron*.
Here, a disturbance of the normal equilibrium between intrarenal 
vasoactive substances, in conjunction with an increase in the 
density of vascular angiotensin II receptors, may result in an 
enhanced local generation of angiotensin XI. This angiotensin IX 
has been shown to result in an inappropriate increase in renal 
vascular resistance, thereby reducing renal perfusion. The 
observations that oestrogen* can cause both structural (50) and 
functional disturbances of the renal circulation in addition to their 
known influence on intrarenal vasoactive substances suggests that 
oestrogen* may play a role, under certain circumstances, in either 
the Initiation or maintenance of certain renal disorders in women.
In this context, the increased incidence of autoimmune disease, 
particularly immune complex disease, seen in females (human and 
several animal species), may be related to hormonal status.
Support for this view may be derived from the report of Friedman, 
et al (202). These workers have shown that oestrogen may affect 
Fc receptor-bearing cells that participate in the handling of 
immune complexes, thereby altering the clinical expression of the 
disease.
The primary objective of this investigation has been to 
contribute to a better comprehension of the little-understood 
subject of the involvement of intrarenal vasoactive substances
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In the Modulation of renal haemodynamics during oestrogen treatnent. 
In the light of this investigation, there need be an increased 
awareness of a potentially hamful effect of oestrogen on the 
renal circulation, particularly in women ingesting oral 
contraceptives.
1??
APPENDIX
D«nth of Anaesthesia and Haemodynamic Xgaaureaca lfl
The effect of anaesthesia on cardiovascular 
stability has been described in section 2,3.2 (p 18), 
In order to ainialse this effect it ia critical that 
a consistent depth of anaeetheaia be attained at the 
point of ineasureaent of haenodynaaic variables. Por 
the purpose of this study therefore, measureaents of 
both mean arterial pressure and the remaining 
haenodynaaic variables have been aade at the lightest 
possible surgical olane of anaesthesia (as determined 
by pain and blink reflexes, and aonltoring both blood 
pressure and the respiratory rhytha).
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